Research

Faculty


Jenifer Allsworth, Ph.D.
Research Associate Professor Department of Biomedical & Health Informatics
  • Ph.D. — Epidemiology, Brown University
  • Research Interests: Impact of social factors, including race, violence, and poverty, on obstetric and gynecologic outcomes; the use of social media for delivery of weight gain interventions among disadvantaged reproductive-aged women at risk for obesity; and the impact of alterations of the vaginal microbiome on health outcomes.
Photo of Jannette Berkley-Patton M.A., PhD
Jannette Berkley-Patton M.A., PhD
Associate Professor Biomedical & Health Informatics
  • University of Missouri-Kansas City, Post doctorate (Psychology HIV/AIDS, 2008)
  • University of Kansas, Ph.D. (Psychology HIV/AIDS, 2004)
  • University of Kansas, M.A. (Human Development and Family Life, 1997)
  • University of Kansas, B.S. (Electrical Engineering, 1988)
More info

Biography

Dr. Berkley-Patton is an associate professor in the UMKC School of Medicine’s Department of Biomedical and Health informatics. She received both her master’s degree in human development and family life, and a doctorate in developmental psychology HIV/AIDS at the University of Kansas. She joined the University of Missouri-Kansas City in 2005 in a postdoctoral fellowship position founded by the National Institute of Mental Health in the Department of Psychology. Dr. Berkley-Patton received a tenure as an associate professor in the UMKC Department of Psychology, where she still remains as an adjunct. She leads the unconquered path of African American and community health research for the UMKC School of Medicine faculty. One of her noted research projects, Taking It to the Pews, was funded with a $3.2 million dollar grant from the National Institute of Mental Health to assess HIV testing. She is the director of the UMKC Community Health Research Group, which supports collaborative community research, and provides doctoral and undergraduate training in community participatory research.

Dr. Berkley-Patton has been awarded many honors and professional memberships, including the Heartland Health Network and the National institute of Minority Health and health Disparities. She is a reviewer for both the University of Missouri Research Board and Centers for Disease Control and Prevention, where she helps improve public health practices through translational research.

Research Interest

Dr. Berkley-Patton interests include helping improve the health of African Americans, where she used collaborative, community-based approaches to allow her to launch new innovative research studies in several settings. She has led and contributed to several community-based intervention trials using a range of intervention strategies from individual behavior change for improving health behavior in large community-based studies, including studies focused on HIV/STDs, HIV medication adherence, diabetes and heart disease/stroke. She uses community based participatory research approaches, in conducting increased HIV screening rates in African American churches.

Photo of Xiang-Ping Chu, M.D., Ph.D.
Xiang-Ping Chu, M.D., Ph.D.
Associate Professor with Tenure Basic Medical Science, Neuroscience Work M3-417 Work Phone: (816) 235-2248
  • Robert S. Dow Neurobiology Laboratories, Legacy Research Institute, Postdoctoral Fellowship (Neurobiology, 2004)
  • Fudan University Shanghai Medical College, Ph.D. (Physiology, 1999)
  • Fudan University Shanghai Medical College, MS (Physiology 1996)
  • Jiangsu University School of Medicine, MD (Clinical Medicine, 1989)
More info

Biography

Dr. Chu earned his medical degree from Jiangsu University School of Medicine in 1989, and his PhD degree from Fudan University Shanghai Medical College in 1999, both in the People’s Republic of China. He then came to America for postdoctoral training at the Legacy Research Institute in Portland, Oregon in 2000. He received a postdoctoral fellowship from the American Heart Association (AHA) in 2002 and subsequently received a beginning grant-in-aid in 2004 and scientist development grant in 2007, both from the AHA. While at the Legacy Research Institute, Dr. Chu was promoted from research associate to senior research associate, to assistant scientist. In 2008, he was recruited to the UMKC School of Medicine as a tenure-track Assistant Professor to establish an advanced, independent electrophysiology laboratory in a strategic expansion of neuroscience research program. In 2014, Dr. Chu was promoted to Associate Professor with tenure. His research focuses on the role of ion channels and membrane receptors in the pathogenesis of neurological disorders such as stroke and drug addiction. While at UMKC, his research has been supported by the National Institute of Health (NIH) and the AHA. Dr. Chu teaches medical neuroscience and physiology courses and is a member of UMKC’s doctoral faculty. He has published 3 book chapters and more than 50 peer-reviewed articles with an H-index of 18, and has served as a peer-reviewer for over 30 scientific journals. Dr. Chu currently serves on Editorial Boards for Advances in Neuroscience, International Journal of Physiology, Pathophysiology & Pharmacology (IJPPP), ISRN Physiology, and Scientific Reports. Dr. Chu also serves on grant study sections for the AHA, Medical Research Council of UK, Ataxia Foundation of UK, and the University of Missouri Research Board (UMRB).

Research Interest

One of my research interests is to understand the functional role of ion channels in ischemic brain injury. Brain ischemia induces various biochemical changes, which can activate various ion channels, including Acid-Sensing Ion Channels (ASICs). During hypoxia/ischemia, increased anerobic glycolysis due to the lack of blood and oxygen supply leads to lactic acid accumulation, causing a reduction in pH, and acidosis. For many years, acidosis has been known to play an important role in the pathology of neuronal injury. However, the cellular and molecular mechanisms underlying acidosis-induced injury remain elusive. Recently we have demonstrated that activation of newly described

ASICs contribute to neuronal injury, particularly those containing the ASIC1a subunit. My aim is to explore the potential mechanisms by which ASIC’s are involved in the pathogenesis of ischemic brain injury, particularly the extent to which they might be modulated/regulated by endogenous molecules (e.g. glucose and zinc). ASICs localize to synapses and proton as a neurotransmitter released from synaptic vesicles activates ASICs during neurotransmission. I am also interested in studying the functional role of ASICs in the brain and the interaction between ASICs and other ion channels/receptors (for example, glutamate receptors, dopamine receptors et al.,) during physiological or pathological conditions such as drug abuse. We want to determine whether ASICs play any roles in the pathogenesis of drug abuse or interact with other receptors in the brain in response to psychostimulants.

Mentoring Area

I am interested in mentoring students who have interests in neurological diseases such as drug abuse and ischemic brain injury using a combination of patch-clamp recording, fluorescence-imaging, gene transfection and knockdown, cell injury assay and behavior measurement techniques.

Recent Publications

*Chu XP, Grasing KA, Wang JQ. Acid-sensing ion channels contribute to neurotoxicity. Transl Stroke Res. 5(1):69-78, 2014. *Corresponding author.

Jing L, *Chu XP, *Zha XM. Three distinct motifs within the C-terminus of ASIC1a regulate its surface trafficking. Neuroscience. 247: 321-327, 2013. *Corresponding author.

Jiang Q, Wang CM, Fibuch EE, Wang JQ, *Chu XP. Differential regulation of locomotor activity to acute and chronic cocaine administration in acid-sensing ion channels 1a and 2 in adult mice. Neuroscience. 246C:170-178, 2013. *Corresponding author.

*Chu XP, Xiong ZG. Acid-sensing ion channels in pathological conditions. Adv Exp Med Biol. 961:419-31, 2013. *Corresponding author.

Jiang Q, Zha XM, *Chu XP. Inhibition of human acid-sensing ion channel 1b by zinc. Int J Physiol Pathophysiol Pharmacol4(2):84-93, 2012. *Corresponding author.

Wang JQ, Chu XP, Guo ML, Jin DZ, Xue B, Berry TJ, Fibuch EE, Mao LM. Modulation of ionotropic glutamate receptors and acid-sensing ion channels by nitric oxide. Front Physiol. 3:164, 2012.

*Chu XP, *Jing L,*Jiang YQ, Collier DM, Wang B, Jiang Q, Snyder PM and Zha XM. N-Glycosylation of ASIC1a regulates its trafficking and acidosis-induced spine remodeling. J Neurosci.  32(12):4080-4091, 2012. *These authors contributed equally.

*Chu XP, Xiong ZG. Physiological and pathological functions of acid-sensing ion channels in central nervous system. Curr Drug Targets. 13(2):263-271, 2012. *Corresponding author.

*Chu XP, Papasian CJ, Wang JQ and Xiong ZG. Modulation of Acid-Sensing Ion Channels: Molecular Mechanisms and Therapeutic Potential. Int J Physiol Pharmacol. 3(4):288-308, 2011. *Corresponding author.

Jing L, Jiang Q, Jiang YQ, Chu XP, and Zha XM. Interaction between the first transmembrane domain and the wrist of acid-sensing ion channel 1a is critical for its maturation and trafficking.  PLoS One, 6(10):e26909, 2011.

Jiang Q, Inoue K, Wu X, Papasian CJ, Wang JQ, Xiong ZG, *Chu XP. Cysteine 149 in the extracellular finger domain of ASIC1b subunit is critical for zinc-mediated inhibition. Neuroscience, 193: 89-99, 2011. *Corresponding author.

Duan B, Wang YZ, Yang T, Chu XP, Yu Y, Huang Y, Cao H, Hansen J, Simon RP, Zhu MX, Xiong ZG, Xu TL. Extracellular spermine exacerbates ischemic neuronal injury through sensitization of ASIC1a channels to extracellular acidosis. J Neurosci. 31: 2101-2112, 2011.

Van Dolah DK, Mao LM, Shaffer C, Guo ML, Fibuch EE, Chu XP, Buch S, Wang JQ. Reversible palmitoylation regulates surface stability of AMPA receptors in the nucleus accumbens in response to cocaine in vivo. Bio Psychiatry. 69: 1035-1042, 2011.

Lin J, Chu XP, Maysami S, Li M, Si H, Cottrell JE, Simon RP, Xiong ZG. Inhibition of acid-sensing ion channel currents by lidocaine in cultured mouse cortical neurons. Anesth Analg. 112:977-981, 2011.

*Chu XP, *Coombes E, *Jiang J, Inoue K, Seeds J, Branigan D, Simon RP, Xiong ZG. Pathophysiological relevant levels of hydrogen peroxide induces glutamate-independent neurodegeneration that involves activation of TRPM7 channels. Antioxid Redox Signal. 14: 1815-1827, 2011. *These authors contributed equally.

Suman A, Mehta B, Guo ML, Chu XP, Fibuch EE, Mao LM and Wang JQ. Alterations in acid-sensing ion channel expression in the rat forebrain following chronic amphetamine administration. Neurosci Res. 68: 1-8, 2010.

Jiang Q, Papasian CJ, Wang JQ, Xiong ZG and *Chu XP. Inhibitory regulation of acid-sensing ion channel 3 by zinc. Neuroscience. 169: 574-583, 2010. *Corresponding author.

*Chu XP, *Mao LM, *Wang W, Zhang GC, Liu XY, Yang YJ, Haines M, Papasian CJ, Fibuch EE, Buch S, Chen JG, Wang JQ. Stability of surface NMDA receptors controls synaptic and behavioral adaptations to amphetamine. Nat Neurosci. 12: 602-10, 2009. *These authors contributed equally.

Jiang Q, Li MH, Papasian CJ, Branigan D, Xiong ZG, Wang JQ, *Chu XP. Characterization of acid-sensing ion channels in medium spiny neurons of mouse striatum. Neuroscience. 162: 55-66, 2009. *Corresponding author.

Zhang GC, Mao LM, Wang JQ, *Chu XP. Upregulation of acid-sensing ion channel 1 protein expression by chronic administration of cocaine in the mouse striatum in vivo. Neurosci Lett. 459:119-22, 2009. *Corresponding author.

Jiang J, Li MH, Inoue K, Chu XP, Seeds J, and Xiong ZG. TRPM7-like current in human head and neck carcinoma cells: role in cell proliferation. Cancer Res.,67:10929-38, 2007.

Liu X, Chu XP, Mao L, Wang M, Lan H, Li MH, Zhang G, Parelkar NK, Haines M, Neve KA, Liu F, Xiong ZG, and Wang JQ. Modulation of D2R/NR2B interactions in response to cocaine. Neuron, 52, 897-909, 2006.

Chu XP, Close N, Saugstad JA, and Xiong ZG. ASIC1a-specific modulation of acid-sensing ion channels in mouse cortical neurons by redox reagents. J. Neurosci., 26:5329-5339, 2006.

Xiong ZG, *Chu XP, *Zhu XM, Minami M, Hey J, Wemmie JA, Price M, Welsh MJ, and Simon RP.  Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell. 118(6): 687-698, 2004. *These authors contributed equally.

Chu XP, Wemmie JA, Wang WZ, Zhu XM, Saugstad JA, Price MP, Simon RP, Xiong ZG.   Subunit-dependent High-Affinity Zinc Inhibition of Acid-Sensing Ion Channels. J. Neurosci., 24 (40): 8678-8689, 2004.

Photo of Akin Cil, M.D.
Akin Cil, M.D.
Associate Professor, Department Vice Chair & Franklin D. Dickson/Missouri Endowed Associate Professor of Orthopaedic Research Truman Medical Center Hospital HillDepartment of Orthopaedic Surgery
More info

Dr. Akin Cil received his medical training at the Hacettepe University Faculty of Medicine in Turkey. Dr. Cil then emigrated to the United States where he completed the Adult Reconstructive Fellowship at Baylor University, the Upper Extremity Reconstructive Fellowship at the Mayo Clinic, and the Pediatric Orthopaedic Sports Medicine Fellowship at Harvard before joining the faculty at UMKC in 2008. In 2012 Dr. Cil was named the Franklin D. Dickson/Missouri Endowed Associate Professor of Orthopaedic Research because of his collaborative research with colleagues in the Department of Civil & Mechanical Engineering in UMKC’s School of Computing and Engineering.

Photo of David J. Cohen, M.D., M.Sc.
David J. Cohen, M.D., M.Sc.
Work Phone: (816) 932-4581
  • Director of Cardiovascular Research – Saint Luke’s Mid America Heart Institute
  • Missouri Endowed Professor of Cardiovascular Research
More info

 

Current Research Activities & Interests

Dr. Cohen is the Medical Director of the the Health Economics and Technology Assessment (HETA) group of Saint Luke’s Mid America Heart Institute. This is a multidisciplinary research group that includes health economists, biostatisicians, decision analyst/modelers, and clinical scientists with a broad aim of improving health care by applying formal cost-effectiveness methodology to novel interventions for the diagnosis and treatment of cardiovascular disease.  Currently, these efforts include a diverse range of projects including development of computer-based simulation models to aid in identifying appropriate targets for new technologies as well as primary economic data collection alongside pivotal clinical trials to evaluate cost-effectiveness of new therapeutic modalities (e.g., stents, glycoprotein 2b/3a blockers, vascular brachytherapy, etc.).

An additional focus of our research is in the extension of traditional cardiovascular outcomes research by collection of patient-centered outcomes (health status, quality of life) among patients undergoing treatment for cardiovascular disease.  These efforts are aimed at identifying alternative treatments or patterns of care that are associated with improved long-term quality of life for patients with coronary heart disease, structural/valvular heart disease, as well as cardiac arrhythmias.  Through primary data collection in a variety of clinical trial and practice settings, these data are valuable to patients, clinicians, and policy-makers who need to better  understand the relationship between traditional “hard” clinical outcomes and overall quality of life among patients with cardiovascular disease.

Finally, we have had a longstanding interest in understanding the short- and long-term outcomes of new devices for percutaneous management of coronary artery disease and valvular heart disease and identifying the optimal target populations and techniques for these devices

 

Selected Publications

Cohen DJ, Kuntz RE, Gordon SPF, Piana RN, Safian RD, McKay RG, Baim DS, Grossman W, Diver DJ.  Predictors of long-term outcome after percutaneous balloon mitral valvuloplasty.  N Engl J Med 1992; 327: 1329-35.

Cohen DJ, Breall JA, Ho KKL, Kuntz RE, Goldman L, Baim DS, Weinstein MC.  Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease: Use of a decision-analytic model.  Circulation 1994;89:1859-1874.

Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, Leon MB, Moses JW, Carrozza JP, Zidar JP, Kuntz RE.  Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the SIRIUS trial.  Circulation 2004;110:508-514.

Ryan JW, Peterson ED, Chen AY, Roe MT, Ohman EM, Cannon CP, Berger PB, Saucedo JF, DeLong ER, Normand SL, Pollack CV, Cohen DJ.  Optimal timing of intervention in non-ST segment elevation acute coronary syndromes: Insights from the CRUSADE Registry.  Circulation2005;112:3049-57.

Ryan J, Linde-Zwirble W, Engelhart L, Cooper L, Cohen DJ.  Temporal trends in coronary revascularization procedures, outcomes, and costs in the bare metal stent and drug-eluting stent eras: Results from the US Medicare Program.  Circulation 2009;119:952-61.

Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ.  Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned PCI:  Results from the TRITON-TIMI 38 trial.  Circulation 2010;71-79.

Cohen DJ, Van Hout B, Serruys PW, Mohr FW, Macaya C, den Jeijer P, Vrakking MM, Wang K, Mahoney EM, Audi S, Leadley K, Dawkins KD, Kappetein AP on behalf of the SYNTAX Investigators.  Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery.  N Engl J Med 2011;364;1016-26.

Venkitachalam L, Lei Y, Stolker JM, Mahoney EM, Amin AP, Lindsey JB, Kennedy KF, Pencina MJ, Lopez JJ, Kleiman NS, Cohen DJ.  Clinical and economic outcomes of liberal vs. selective drug-eluting stent use:  Insights from temporal analysis of the multicenter EVENT registry. Circulation2011;124:1028-37.

Venkitachalam L, Lei Y, Magnuson EA, Chan PS, Stolker JM, Kennedy KF, Kleiman NS, Cohen DJ.  Survival benefit with drug-eluting stents in observational studies: Fact or artifact?  Circulation: Cardiovasc Qual Outcomes 2011;587-94.

Reynolds MR, Magnuson EA, Wang K, Lei Y, Vilain K, Walczak J, Kodali SK, Lasala JM, O’Neill WW, Davidson CJ, Smith CR, Leon MB, Cohen DJ.

Cost effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: Results from the PARTNER trial (Cohort B).Circulation 2012;125:1102-9.

Arnold SV, Magnuson EA, Wang K, Serruys PW, Kappetein AP, Mohr FW, Cohen DJ.  Do differences in repeat revascularization explain the antianginal benefits of bypass surgery vs. percutaneous coronary intervention?  Implications for future treatment comparisons.  Circulation: Cardiovasc Qual Outcomes 2012;5:267-75

Reynolds MR, Magnuson EA, Lei Y, Wang K, Vilain K, Li H, Walczak J, Pinto DS, Thourani VH, Svennson LG, Mack MJ, Miller DC, Satler LE, Bavaria J, Smith CR, Leon MB, Cohen DJ.  Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in patients with severe aortic stenosis: Results from the PARTNER Trial (Cohort A).  J Am Coll Cardiol 2012 (in press).

Magnuson EA, Farkouh ME, Fuster V, Wang K, Vilain K, Li H, Appelwick J, Muratov V, Sleeper LA, Boineau R, Abdallah M, Cohen DJ. Cost-Effectiveness of Percutaneous Coronary Intervention with Drug Eluting Stents versus Bypass Surgery for Patients with Diabetes and Multivessel Coronary Artery Disease:  Results from the FREEDOM Trial. Circulation 2013 (in press).

Photo of Mingui Fu, Ph.D.
Mingui Fu, Ph.D.
Associate Professor Immunology, Shock/Trauma Research CenterBasic Medical Science Work MG-101A Work Phone: (816) 235-2193
  • M.S.:   Xian Medical University, China, 1994
  • Ph.D.:   Peking University Health Science Center, China, 2000
  • Postdoctoral Fellow: Morehouse School of Medicine, Atlanta, 2003 and UT Southwestern Medical Center, Dallas, 2006
More info
Research Area:

Molecular Insights in Inflammation and Inflammatory Diseases

Topics of Interest:
  • Regulatory mechanisms of septic shock
  • Signal transduction in macrophage activation
  • RNA metabolism in immune regulation
  • Negative regulation of Toll-like receptor signaling
  • Molecular signaling of vascular endothelial inflammation, injury and repair
  • Novel therapeutic targets for human inflammatory diseases including atherosclerosis, sepsis and viral infection
Recent Projects:
  1. The Roles of CCCH-Zinc Finger Proteins in the Regulation of Inflammation.
         Nearly 60 CCCH-zinc finger proteins have been identified in humans and mice. These proteins are involved in the regulation of multiple steps of RNA metabolism, including mRNA splicing, polyadenylation, transportation, translation, and decay. Several CCCH-zinc finger proteins, such as tristetraprolin, Roquin and MCPIP1, are crucial for many aspects of immune responses via targeting mRNA degradation and other mechanisms. Others are involved in the regulation of cell differentiation and cancer cell growth. In the past ten years, we have been working on a novel CCCH-zinc finger containing protein, MCPIP1, in the regulation of both innate and adaptive immunity. Using transgenic and knockout mouse models, we are studying the physiological role and mechanisms of MCPIP1 in inflammatory response and immunity and the involvement of MCPIP1 in septic shock, atherosclerosis and autoimmune diseases.
  2. Novel Molecular Regulators in Vascular Endothelial Inflammation, Injury and Repair.
         Vascular endothelium is a multifunctional and critical interface between blood stream and vascular wall. Meanwhile, vascular endothelium is also the largest endocrine, paracrine and metabolic organ. Recent studies suggest that there is endothelial dysfunction at the early stage of cardiovascular diseases and stroke caused by atherosclerosis, hypertension and diabetes. In addition, the initial event in bacterial and viral infection-caused multi-organ injury is vascular endothelial damage and dysfunction. So that vascular endothelial inflammation and dysfunction is a common pathological step and basis for cardiovascular diseases and stroke and acute organ injury. Improving the function of vascular endothelium and repairing the damaged vascular endothelium would be a critical step for treatment of cardiovascular diseases and stroke and acute organ injury. Using expression profiling and bioinformatics, we recently identified an adipocyte-enriched protein, adiporedoxin, as a negative regulator of endothelial activation (Sci Rep, 2016). In addition, we have identified a TRIM protein as a novel determinant of vascular endothelial inflammation via targeting VCAM-1 degradation. Currently, we are studying the roles and mechanisms of these proteins in vascular inflammation, atherosclerosis, sepsis and cerebral small vascular disease.
Selected Publications:
  1. Liang J, Wang J, Azfer A, Song W, Tromp G, Kolattukudy PE, Fu M#. A novel CCCH-Zinc finger protein family regulates proinflammatory activation of macrophages. J Biol Chem. 2008, 283:6337-6346.
  2. Liang J, Lei T, Song Y, Yanes N and Fu M#. RNA-destabilizing factor Tristetraprolin negatively regulates NF-κB signaling. J Biol Chem. 2009, 284: 29383-29390.
  3. Liang J, Saad Y, Lei T, Wang J, Qi D, Yang Q, Kolattukudy PE and Fu M#. MCP-induced protein 1 deubiquitinating TRAFs and negatively regulate JNK and NF-κB signaling. J Exp Med, 2010, 207:2959-73.
  4. Qi D, Huang S, Miao R, She ZG, Quinn T, Chang Y, Liu J, Fan D, Chen YE, Fu M#. Monocyte chemotactic protein-induced protein 1 (MCPIP1) suppresses stress granule formation and determines apoptosis under stress. J Biol Chem. 2011, 286(48):41692-700.
  5. Zhang Y, Breevoort SR, Angdisen J, Fu M, Schmidt DR, Holmstrom AR, Kliewer SA, Mangelsdorf DJ, Schulman IG. Liver LXRα expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Invest, 2012, 122(5):1688-99.
  6. Zhang J, Zhang Y, Sun T, Chandalia M, Abate N, Fan D, Xin HB, Chen YE# and Fu M#. Dietary obesity induced Egr-1 in adipocytes facilitates energy storage via suppression of FOXC2. Sci Rep. 2013, 3:1476.
  7. Niu J, Shi Y, Xue J, Xu M, Miao R, Huang S, Chen ZJ, Fu M, Wu Z-H. DNA damage-induced MCPIP1 negatively regulates NF-κB activation by facilitating USP10-dependent disassembly of linear polyubiquitin chain. EMBO J, 2013, 32:3206-3219.
  8. Liu S, Qiu C, Miao R, Zhou J, Fu W, Zhu L, Zhang L, Xu J, Fan D, Li K, Fu M#, Wang T#. MCPIP1 restricts HIV infection and is rapidly degraded in activated CD4+ T cells. Proc Natl Acad Sci U S A., 2013, 110(47):19083-8.
  9. Yao H, Ma R, Yang L, Hu G, Chen X, Duan M, Kook Y, Niu F, Liao K, Fu M, Hu G, Kolattukudy P, Buch S. MiR-9 promotes microglial activation by targeting MCPIP1. Nat Commun. 2014. 5:4386.
  10. Jeltsch KM, Hu D, Brenner S, Zöller J, Heinz GA, Nagel D, Vogel KU, Rehage N, Warth SC, Edelmann SL, Gloury R, Martin N, Lohs C, Lech M, Stehklein JE, Geerlof A, Kremmer E, Weber A, Anders HJ, Schmitz I, Schmidt-Supprian M, Fu M, Holtmann H, Krappmann D, Ruland J, Kallies A, Heikenwalder M & Heissmeyer V. Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote TH17 differentiation. Nat Immunol. 2014, 15(11):1079-1089.
  11. Huang S, Liu S, Fu JJ, Tony Wang T, Yao X, Kumar A, Liu G, Fu M#. Monocyte Chemotactic Protein-induced Protein 1 and 4 Form a Complex but Act Independently in Regulation of Interleukin-6 mRNA Degradation. J Biol Chem. 2015 Aug 21;290(34):20782-92.
  12. He H, Guo F, Li Y, Saaoud F, Kimmis BD, Sandhu J, Fan M, Maulik D, Lessner S, Fan D, Jiang ZS#, and Fu M#. Adiporedoxin suppresses endothelial activation via inhibiting MAPK and NF-κB signaling. Sci Rep. 2016 (in press).
  13. Jiang MX, Hong X, Liao BB, Shi SZ, Lai XF, Zheng HY, Xie L, Wang Y, Wang XL, Xin HB, Fu M#, and Deng KY#. Expression profiling identifies a novel group of TRIM proteins involving in the proinflammatory activation of macrophages. Sci Rep. 2016 (in press).

Photo of Bill Geis, Ph.D.
Bill Geis, Ph.D.
Clinical Assistant Professor Department of Psychiatry
  • Kansas City Suicide Awareness and Prevention Program (KCSAPP), Vice-President for Programming
More info

Research Interests

Bill D. Geis, Ph.D., is the director of Behavioral Health Research at the UMKC School of Medicine and practices at the Center for Behavioral Medicine (CBM) and his clinic, The West Plaza Clinic, in Kansas City. Geis is also a founding member and vice president of training for the Kansas City Suicide Awareness and Prevention Program (KCSAPP). With nearly 30 years of experience in research, teaching and practicing clinical psychology, Geis continues to be a supervising faculty member at CBM, an adjunct professor of psychology at the University of Kansas and adjunct professor of occupational therapy at the University of Kansas School of Medicine.

He received a Bachelor of Arts in psychology, history and classics from KU. He went on to receive a master’s degree and Ph.D. in clinical psychology from the University. Geis completed a one-year internship at the Indiana University School of Medicine and a two-year, post-doctoral fellowship in clinical psychology at the Menninger Foundation in Topeka, Kan. He has generated and participated in more than $10 million dollars in research and demonstration project funding involving substance abuse, psychiatric disability, cancer support, homelessness interventions, domestic violence, and in recent years, suicide prevention and suicide assessment utilizing thought patterns to enhance risk assessment. He has received funding and support from the Substance Abuse and Mental Health Services Administration (SAMHSA), the Centers for Disease Control, the Robert Wood Johnson Foundation, the Ewing Marion Kauffman Foundation and the Health Care Foundation of Greater Kansas City. His current funding in suicide research enjoys support from SAMHSA (involving a state-wide suicide prevention plan) and the Health Care Foundation of Greater Kansas City (enhanced suicide risk triage).

 

Selected Publications

Geis, B.D., & Edlavitch, S. (2011). Kansas City Public Mental Health Suicide Intervention (PMHSI): From Triage and Intervention to Sustainable System Transformation-2006-2010. The Health Care Foundation of Greater Kansas City.

Geis, B.D., Edlavitch, S., Newman, F., Van Whitlock, R, Munro, S, Lang, M, and Tosh, D. (2013). Latent Dimensions of Suicide-Related Thinking: A Complex Variable Prediction Model. Submitted to Journal of Abnormal Psychology.

Geis, B.D., Edlavitch, S, Newman, F., Van Whitlock, R, Munro, S, Lang, M, and Tosh, D. (2013). The Core Suicide Risk System: The Association of Suicide Risk Profiles and Clinical Validity Measures. Submitted to Archives of Suicide Research.

Geis, B.D., Edlavitch, S, Van Whitlock, R, Munro, S, Lang, M, and Tosh, D. (2013). The Core Suicide Risk System: The Association of Suicide Risk Profiles and Personality and Validity Information. Submitted to the Journal of Clinical Psychology.

Other Selected Publications / Papers / Presentations

Geis, B. (2006). Expanding school suicide prevention: Beyond warning signs to the promotion of help-seeking behavior. MSCA’s The Counseling Interviewer. Fall, Vol. 39 (1), 22-24.
Geis, B.D. & Edlavitch, S. (2003). Kansas City’s ANSWER: A multi-county coalition for teen suicide prevention. SAMHSA Youth Violence Prevention Cooperative Agreement (Catalog Number: 93-230). March 2003.

Geis, B.D. & Gerrard, M. (1984). Predicting male and female contraceptive behavior: A discriminant analysis of groups high, moderate, and low in contraceptive effectiveness. Journal of Personality and Social Psychology, Vol 46(3), Mar, 669-680.
Geis, B.D. (1986). A structural equation model of female contraceptive behavior. Lawrence, KS., University of Kansas Press.

Geis B, Edlavitch SA. Suicide-Related Cognitive-Diagnostic Variables in 5 Urban Settings, American Association of Suicidology, Orlando, April 23, 2010.

Geis B, Edlavitch SA., Thought Patterns and Suicide Risk: Eight Factor-Derived Suicide Profiles, 44th Annual Meeting of the American Association of Suicidology, Portland, Oregon, April 20, 2011.

Geis BD, Edlavitch SA., Eight Empirically-Derived Suicide Risk Patterns: Validity Information and Video Illustrations of Profile Types, 45th American Association of Suicidology Annual Conference, Baltimore, Maryland, April 19, 2012.

Geis BD, Edlavitch SA., Suicide Risk System: Eight Thought Patterns Impacting Suicide Risk, 9th Annual Midwest Conference on Problem Gambling and Substance Abuse: Utilizing Evidence‐Based Practices, Kansas City, Missouri, June 6‐8, 2012.

Geis, Bill D. Using Social Indicator Data to Develop, Organize and Validate Strategies for Substance Abuse Treatment. The Robert Wood Johnson Foundation’s Demand Treatment Initiative. Houston, Texas. November 30 and December 1, 2000.

Geis, Bill D. The Six Month Report of Substance Abuse and Related Harms: January 1, 2000 to June 30, 2000. Volume V. Move UP, Inc. A Report for the Robert Wood Johnson Foundation on substance abuse in Kansas City, Missouri, September 14, 2000.

Geis, Bill D. “Using Social Indicators to Fight Substance Abuse.” 108th American Psychological Association Convention. Washington, D.C., August 7, 2000

Geis, Bill D. “Kansas City’s Fighting Back Substance Abuse Prevention Initiative: Local Data, Leadership and Linkage.” Using Community and Neighborhood-Level Indicators to Measure and Guide Coalition Strategy. Invited Address: Department of Health and Human Services. Hubert Humphrey Building. Washington, D.C., June 9, 2000.

Photo of Mary M. Gerkovich, Ph.D.
Mary M. Gerkovich, Ph.D.
Associate Professor Office for Health Services & Outcomes ResearchDepartment of Biomedical & Health Informatics
  • 1998 – University of Kansas
  • Research interests: Factors related to the decisions people make about health practices including predictors of both maintaining positive health behaviors and changing unhealthy behaviors; factors that predict risk behavior; and analysis of multidimensional health behavior data sets.
Photo of Matthew C. Gratton, M.D.
Matthew C. Gratton, M.D.
Chairman & Professor – Department of Emergency Medicine Truman Medical Center Hospital HillDepartment of Emergency Medicine
  • Undergraduate School:  Rockhurst College
  • Medical School:  Saint Louis University School of Medicine
  • EM Residency:  Truman Medical Center/UMKC School of Medicine
  • ABEM Diplomate:  1984/1994/2004/2014
More info

Biography

Dr. Gratton was born and raised in Kansas City, Missouri.  He graduated from St. Louis University School of Medicine in 1979 and completed a transitional internship at the National Naval Medical Center, Bethesda, Maryland in 1980.  He completed his emergency medicine residency at Truman Medical Center in 1983 and has been board certified since 1984.

After completing several years of active duty service in the Navy, Dr Gratton returned to Truman where he focused on Emergency Medical Services (EMS.)  From 1989 – 1993 he was the Medical Director for MAST, the Kansas City, Missouri public utility model ambulance service and from 1999 – 2004 and again from 2006 – 2007 was the EMS Medical Director for Kansas City, Missouri.  During this tenure the KCMO EMS System was comprised of MAST (about 300 paramedics and EMTs) and the KCMO Fire Department (about 1,000 EMTs and First Responders).

Dr. Gratton was a member of the US Navy Reserve from 1976 through 2007 and served in several overseas locations.  He had four recalls to active duty, including deployments to Bahrain in Operation Desert Storm in 1991 and Iraq in Operation Iraqi Freedom in 2005.  He retired from the Navy in the fall of 2007 as a Captain.  Military awards include: Combat Action Ribbon, Navy Commendation Medal, Bronze Star, Legion of Merit and Fleet Marine Force Warfare Officer Device.

Dr. Gratton was appointed Chair in August 2007.  He has published numerous abstracts and articles on EMS related and other topics.  He is an oral examiner for the American Board of Emergency Medicine and an Associate Editor for Academic Emergency Medicine. Honors include: Staff Physician of the Year 1989, Mid-America Regional Council Emergency Physician of the Year 1992, Elmer Pierson Teaching Award (UMKC School of Medicine) 1993, Frank Mitchell EMS Physician of the Year (Missouri EMS Association) 2000 and numerous KCMO City Council Resolutions. Dr Gratton is a Past President of the TMC Medical Dental Staff and a former Chair of Board of Directors of University Physician Associates.

Selected Publications

Barksdale A, Hackman J, Bonham A, Gratton M.  Cardiology Clinic Follow-Up Did Not Decrease Return Visits to the ED for Chest Pain Patients. Am J Emerg Med 2014; (32): 1208-1211                                                         

Gratton M, Garza A, Salomone III J, McElroy J, Shearer J. Ambulance Staging for Potentially Dangerous Scenes:  Another Hidden Component of Response Time.  Prehosp Emerg Care 2010; 14: 340-344

Garza A, Gratton MC, Salomone JA, Lindholm D, McElroy J, Archer R.  Improved Patient Survival Using a Modified Resuscitation Protocol for Out-of-Hospital Cardiac Arrest.  Circulation 2009; 119: 2597-2605

 Garza A, Algren A, Gratton M, Ma OJ: Populations at Risk for Intubation Nonattempt and Failure in the Prehospital Setting.  Prehospital Emergency Care. 2005; 9(2): 163-166

Garza A, Gratton M, Chen J, Carlson B:  The accuracy of diagnosing cardiac arrest by EMS Dispatchers; the calling party effect.  Acad Emerg Med 2003;10(9): 955-960

 Gratton M, Ellison S, Hunt J, Ma OJ:  Prospective determination of medical necessity for ambulance transport by paramedics.  Prehospital Emergency Care 2003;7(4): 466-469

Garza A, Gratton M, Coontz D, Noble E, Ma OJ:  Effect of paramedic experience on oral intubation success rates.  Am J of Emerg Med 2003;25(3): 251-256 

Gratton MC, Lindholm DJ, Campbell JP: Public-access defibrillation, Where do we place the AEDs? Prehospital Emergency Care 1999;4: 303-305

Campbell JP, Gratton MC, Salomone JA, Watson WA:  Ambulance arrival to patient contact:  the hidden component of prehospital response time intervals.  Ann Emerg Med 1993;22: 1254-1257

Gratton MC, Bethke RA, Watson WA, Gaddis GM:  Effect of standing orders on paramedic scene time for trauma patients.  Ann Emerg Med 1991;20: 1306-1309

Gratton MC, Salomone JA, Watson WA:  Clinically significant radiograph misinterpretations at an emergency medicine residency program.  Ann Emerg Med 1990;19: 497-502

Photo of Mark Hoffman, Ph.D.
Mark Hoffman, Ph.D.
Department of Biomedical & Health Informatics

 

  • Research Associate Professor – Biomedical & Health Informatics
  • ResearchAssociate Professor – Pediatrics
  • Children’s Mercy Hospital – Director Translational Bioinformatics
More info

Biography

Dr. Mark Hoffman received his Ph.D. from the University of Wisconsin – Madison and performed post-doctoral research at the National Animal Disease Center in Ames, Iowa. Before joining UMKC, he spent 16 years leading genomics, public health and research initiatives at Cerner Corporation, where he was a Vice President. In addition to his peer-reviewed publications, Mark is an inventor on 16 issued patents.

Research Interests

The integration of genomic information with electronic health records, genomic clinical decision support, the use of informatics to accelerate research and the analysis of large de-identified clinical data sets to reach new insights.

View CV

Photo of Peter Koulen, Ph.D.
Peter Koulen, Ph.D.
Departments of Ophthalmology & Basic Medical Science Work Phone: (816) 404-1824

Professor and Felix and Carmen Sabates Missouri Endowed Chair in Vision Research
Director of Basic Research, Vision Research Center
Department of Ophthalmology

Professor
Department of Basic Medical Science

More info

Research Interest

Dr. Koulen is a Professor of Ophthalmology and Basic Medical Science and the Felix and Carmen Sabates Missouri Endowed Chair in Vision Research at the UMKC School of Medicine. He trained at the Max-Planck-Institute for Brain Research, Yale University and the Marine Biological Laboratory. His research focuses on basic research on and therapy development for chronic diseases of the eye and brain. He is an internationally recognized expert in biophysics, biochemistry and physiology of nerve cells and his research has been funded continually since 2002 by national and international foundations and agencies including the NIH’s National Eye Institute, National Institute on Aging, National Cancer Institute, National Center for Research Resources, National Institute of Diabetes and Digestive and Kidney Diseases, and the U.S. DOD among others. As principal or co-investigator for over $20 million in extramural grant funding for research studies, Dr. Koulen’s research program has fundamental relevance to basic science, translational research and therapy development as evidenced by over 100 peer-reviewed publications in scientific journals, and 6 book chapters. Dr. Koulen has over 20 years of experience in the fields of neuroscience and eye research, drug development, translational research, biological sciences, biostatistics, and routinely interprets complex data sets with distinct public health significance. Dr. Koulen serves as reviewer for more than 50 professional scientific journals, serves on over 15 editorial boards and is editor in chief of two scientific journals. He is a review panel member for several national and international funding agencies including the National Science Foundation, the National Institutes of Health, the U.S. Department of Defense and other national and international government agencies and research foundations. The University of Missouri – Kansas City Board of Trustees recognized Dr. Koulen with the N.T. Veatch Award for Distinguished Research and Creativity in 2013. Through this Faculty Award, UMKC and the UMKC Trustees are recognizing the very best faculties, who have distinguished themselves through scholarship and creativity.

Vision research

Degeneration or acute damage of nerve cells in the retina is a major cause of visual loss and blindness in the United States and worldwide. As diseases such as glaucoma, macular degeneration and diabetic retinopathy affect significant and increasing portions of the U.S. population, including minorities affected by disparities in health care delivery, determining causes, mechanisms of action and subsequently potential treatment strategies will contribute to improving health care, health and performance requiring visual tasks.

The Vision Research Center was founded as and is a well-established collaboration of several UMKC schools and Kansas City Medical Centers and thus offers an unprecedented interdisciplinary synergy with a unified goal: to better diagnose, prevent, and treat eye disease and vision disorders through translational research in order to make a difference in the lives of tens of millions of people worldwide. To this end, the center conducts federally and industry funded basic, translational and clinical research to develop new medical therapies and offers patient care in all subspecialties of ophthalmology. The center’s nationally recognized excellence in research, patient care and medical education contribute to UMKC’s strengths in the life sciences. Objectives of the Vision Research Center are to:

  • Provide a direct avenue for basic and translational research in eye and related diseases,
  • Transfer basic science findings seamlessly into practical use with patients through translational research,
  • Develop new therapy approaches urgently needed by physicians in the US and worldwide,
  • Provide educational excellence,
  • Ensure patients receive the most advanced medical treatments available,
  • Become a national center of excellence for eye research.
Publications:

My NCBI Collections

Photo of Sheshadri Madhusudana MBBS
Sheshadri Madhusudana MBBS
Assistant Professor Truman Medical Center Hosptial HillInternal Medicine

 

  • Specialty: Hematology/Oncology
  • Medical School: JSS Medical College, India
  • Residency: Internal Medicine — UMKC School of Medicine
  • Fellowship: Emergency Medicine — Bangalore, India; Hematology/Oncology — Truman Medical Center, Kansas City, MO

 

Photo of Agostino Molteni, M.D., Ph.D., F.A.C.C.B.
Agostino Molteni, M.D., Ph.D., F.A.C.C.B.
Director of Student Research UMKC School of Medicine
  • Professor of Pathology & Pharmacology – UMKC School of Medicine
  • Professor Emeritus of Pathology – Northwestern University
More info

Research Interests

Dr. Molteni’s main research interest is the study of development of interstitial pulmonary fibrosis (IPF) in several models of experimental lung injury: exposure to radiation and hypoxia, administration of bleomycin and fat embolism syndrome. Also studied is the role played by the renin angiotensin system in the development of fibrosis and the antifibrotic protection of angiotensin converting inhibitors or angiotensin II receptor blockers.

His projects are conducted in cooperation with Dr. Betty Herndon (UMKC SOM); Dr. T. McIff, Dept. of Orthopedic Surgery and Dr. A. Poisner, Dept. of Pharmacology, University of Kansas Medical Center, Dr. B. Uhal, Dept. of Physiology, Michigan State University, Dr. R. Baybutt, Dept. of Health Sciences, Wheaton College, Wheaton, IL., Dr. G Van Den Heuvel, Dept. of Physiology, Eastern Michigan University, Kalamazoo, MI.

Research Career Development Award, National Institutes of Health, 1972
Albert E. Lasker Award, 1980, to NHLBI sharing as principal investigator, Central Laboratory Hypertension Detection and Follow-up Program
Meritorious Service Award, Chicago Heart Association,1982
Clinical Chemists Recognition Award, 1983

Recent research includes the evaluation of exenatide in a rodent model of non-alcoholic liver steatosis, and in particular, the drug’s effect on the pancreas and the thyroid of these animals. This study was performed in cooperation with Dr. Herndon, Dr. Laura Alba, and others of the Dept. of Medicine, in the UMKC SOM. An additional study is the evaluation of pulmonary and cardiac damage in a model of Cux-1 mice expressing the cyclin kinase inhibitors P21 and P27 (Drs Baybutt and Van Den Heuvel).

Selected Publications

Has published more than 200 articles and book chapters and more than 370 presentations at national and international scientific meetings.

Curcumin Effects on Hepatic Steatosis and Histopathology in an Obese Mouse Model. British Journal of Medicine and Medical Research: 5(8): 1017-1023, 2015. Article no BJMMP.2015.112

Fat Embolism sensitizes rats to a “second hit” with LPS: an animal model of Pulmonary Fibrosis: Journal of Trauma and Acute Surgical Care; 783:552-557, 2015

Fat Embolism Syndrome following caesarean section in an obese patient and it’s similarity to an animal model of the same syndrome: a case report. Case reports in Clinical Pathology: Published online 3-3-2015, D01110.5430/crcp.vnp

NF-KB controls Resistance of Human Salivary Gland (HSG) Cells to apoptosis in an in vitro model of Sjögren syndrome. Open Journal of Rheumatology and Auto immune Diseases (OJRA): Vol 4 #3; ID: 2040 128, 2014

Mitigating effect of Captopril and Losartan on Lung Histopathology in a rat model of Fat Embolism. The Journal of Trauma 70 (5):1186-1191; 2011

Biochemical and Histological Effects of Exendin 4 (exenatide) in the rat pancreas. Diabetologia53(1):153-159; 2010

“Persistent and progressive fibrotic changes in a model of fat embolism.” Journal of Trauma 72 (h) 992-998, 2012

“Dietary flaxseed oil protects against bleomycin-induced pulmonary fibrosis in rats.” Pulmonary Medicine, published on line, June 2012 10457031 doi 0.1155/2012/457031

“Urease and Helicobacter spp. Antigens in Pulmonary Granuloma” Journal of Comparative Pathology(2012) http://dx.doi.org/10.1016/j.jcpa.2012.06.011

“Effect of exendin (exenatide) on the thyroid and parathyroid gland in a rat model.” Eur. J., of Pharmacology 2012 http://dx.doi.org/10.1016/j.ejphar.2012.07.024 

Photo of Paula Monaghan-Nichols, Ph.D.
Paula Monaghan-Nichols, Ph.D.
Associate Dean for Research, Professor Basic Medical Sciences Basic Medical Sciences Home M3-C02 Work Phone: (816) 235-6663
  • Trinity College, Dublin, Ireland, BA (Genetics)
  • Medical Research Council, Edinburgh, Scotland, Ph.D. (Genetic Engineering and Molecular Biology)
  • Medical Research Council, Human Genetics Unit, Edinburgh, Scotland, Post-Graduate (Molecular Genetics and Development)
More info

Research and Professional Experience

Postdoctoral Fellow/Research Associate, Molecular Biology of the Cell 1, German Cancer Research Centre, Heidelberg, Germany.

Assistant Professor, Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA

 Associate Professor, Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA

Research Interest

Molecular Genetic Analysis of the Developmental Basis of Neuropsychiatric Disorders

Research Summary

My laboratory focuses on understanding the molecular and developmental basis of emotional and cognitive behavior and psychiatric illness. The long-term goal of my research is to identify both intrinsic and environmental factors that specifically alter the development of areas in the brain that are essential for emotion and cognition.  My laboratory has identified a number of transcriptional repressors (Tlx, Sall1, Sall2, Sall3 and Sall4) that are expressed in the developing forebrain. This research has shown that these genes are express in stem and progenitor cells in the cerebral cortex, and are required to regulate the rate of stem/progenitor cell proliferation and neuronal differentiation.  Using both conditional and classical knockout experiments and in-utero electroporation studies in mice, my laboratory has shown that altering the levels of these proteins during development leads to emotional, behavioral and cognitive abnormalities in adult animals.  Our most recent studies focus on identifying the cellular and biochemical targets of glucocorticoid action on the developing brain in-utero. Synthetic glucocorticoids are administered to mothers at risk for pre-term labor, to stimulate lung maturation and to reduce the risk of intraventricular hemorrhage and necrotizing enterocolitis. Clinical follow up studies indicate that children exposed to steroid in-utero have cognitive abnormalities and an altered stress response. My laboratory is using a combination of molecular, cellular, proteomic, RNA-Seq. and genome wide DNase hypersensitive site mapping to identify the cellular targets of steroid action. These studies have shown that prenatal exposure to glucocorticoids leads to changes in neuronal number and density in the cerebral cortex at birth coupled to long-term alterations in neurite complexity in the prefrontal cortex and hippocampus in adolescents. These anatomical abnormalities are associated with changes in anxiety and depressive like behaviors in adults. Follow up studies include validating our identified targets in human brain and in umbilical cord blood cells.  These findings will for a framework for modifying current clinical dosing regiments in preterm labor to reduce the adverse consequences of premature exposure to corticosteroids in-utero.

Selected Publications

Research Resource: The Dexamethasone Transcriptome in Hypothalamic Embryonic Neural Stem Cells.Frahm KA, Peffer ME, Zhang JY, Luthra S, Chakka AB, Couger MB, Chandran UR, Monaghan AP, DeFranco DB. Mol Endocrinol. 2016 Jan;30(1):144-54.

Genome-wide transcript profiling reveals novel breast cancer-associated intronic sense RNAs.Kim SW, Fishilevich E, Arango-Argoty G, Lin Y, Liu G, Li Z, Monaghan AP, Nichols M, John B. PLoS One. 2015 Mar 23;10(3):e0120296..

Caveolin-1 regulates genomic action of the glucocorticoid receptor in neural stem cells.Peffer ME, Chandran UR, Luthra S, Volonte D, Galbiati F, Garabedian MJ, Monaghan AP, DeFranco DB. Mol Cell Biol. 2014 Jul;34(14):2611-23.

Wu P1, Teot L, Murdoch GH, Monaghan-Nichols P, McFadden K.  Neuropathology of 22q11 Deletion Syndrome in an Infant. Pediatr Dev Pathol. 2014 17(5):386-92.

An in-depth map of polyadenylation sites in cancer. Lin Y, Li Z, Ozsolak F, Kim SW, Arango-Argoty G, Liu TT, Tenenbaum SA, Bailey T, Monaghan AP, Milos PM, John B. Nucleic Acids Res. 2012 Sep 1;40(17):8460-71.

Sall1 regulates cortical neurogenesis and laminar fate specification in mice: implications for neural abnormalities in Townes-Brocks syndrome. Harrison SJ, Nishinakamura R, Jones KR, Monaghan AP. Dis Model Mech. 2012 May;5(3):351-65.

 Comprehensive polyadenylation site maps in yeast and human reveal pervasive alternative polyadenylation. Ozsolak F, Kapranov P, Foissac S, Kim SW, Fishilevich E, Monaghan AP, John B, Milos PM. Cell. 2010 Dec 10;143(6):1018-29. doi: 10.1016/j.cell.

New class of gene-termini-associated human RNAs suggests a novel RNA copying mechanism.Kapranov P, Ozsolak F, Kim SW, Foissac S, Lipson D, Hart C, Roels S, Borel C, Antonarakis SE, Monaghan AP, John B, Milos PM. Nature. 2010 Jul 29;466(7306):642-6. doi: 10.1038/nature09190.

Sall3 is required for the terminal maturation of olfactory glomerular interneurons.Harrison SJ, Parrish M, Monaghan AP. J Comp Neurol. 2008 Apr 10;507(5):1780-94.

Sall1 regulates mitral cell development and olfactory nerve extension in the developing olfactory bulb. Harrison SJ, Nishinakamura R, Monaghan AP. Cereb Cortex. 2008 Jul;18(7):1604-17.

Abnormal development of zinc-containing cortical circuits in the absence of the transcription factor Tailless. Land PW, Monaghan AP. Brain Res Dev Brain Res. 2005 Aug 8;158(1-2):97-101.

The Tlx gene regulates the timing of neurogenesis in the cortex. Roy K, Kuznicki K, Wu Q, Sun Z, Bock D, Schutz G, Vranich N, Monaghan AP. J Neurosci. 2004 Sep 22;24(38):8333-45.

Loss of the Sall3 gene leads to palate deficiency, abnormalities in cranial nerves, and perinatal lethality. Parrish M, Ott T, Lance-Jones C, Schuetz G, Schwaeger-Nickolenko A, Monaghan AP. Mol Cell Biol. 2004 Aug;24(16):7102-12.

Expression of the transcription factor, tailless, is required for formation of superficial cortical layers. Land PW, Monaghan AP. Cereb Cortex. 2003 Sep;13(9):921-31.

Loss of the tailless gene affects forebrain development and emotional behavior. Roy K, Thiels E, Monaghan AP. Physiol Behav. 2002 Dec;77(4-5):595-600.

A new member of the spalt like zinc finger protein family, Msal-3, is expressed in the CNS and sites of epithelial/mesenchymal interaction. Ott T, Parrish M, Bond K, Schwaeger-Nickolenko A, Monaghan AP.= Mech Dev. 2001 Mar;101(1-2):203-7.

Defective limbic system in mice lacking the tailless gene. Monaghan AP, Bock D, Gass P, Schwäger A, Wolfer DP, Lipp HP, Schütz G. Nature. 1997 Dec 4;390(6659):515-7.

Photo of Christopher Papasian, Ph.D. (ABMM)
Christopher Papasian, Ph.D. (ABMM)
Work M3-CO3 Work Phone: (816) 235-5172

Professor & Chairman, Basic Medical Science, UMKC School of Medicine
Microbiology Consultant, Truman Medical Center

  • Microbiology; SUNY Buffalo – Ph.D. (1982)
  • Veterinary Science; University of Idaho – M.S. (1978)
  • Forest Zoology; SUNY College of Environmental Science & Forestry – B.S. (Magna cum laude: 1976)
  • Zoology; Syracuse University – B.S. (Magna cum laude: 1976)
More info
Biography

Chris Papasian is Board Certified in Medical and Public Health Microbiology. He was trained as a classical immunology researcher in both cellular and humoral immunity, then opted to pursue postdoctoral training in Medical and Public Health Microbiology. He served as Director of Diagnostic Microbiology and Immunology Laboratories at major teaching hospitals from 1984-1998. He currently serves as a Microbiology Consultant for Truman Medical Center, a primary teaching hospital for the UMKC School of Medicine.

Dr. Papasian is course director for the Medical Microbiology Course offered to medical students at UMKC.

Research Interest

Dr. Papasian does not currently maintain his own active research laboratory but contributes to the research of several faculty within the department. His primary personal research interest lies in the area of the host response to serious infections.

Editor

Clinical and Vaccine Immunology, 7/2012-Present

Editorial Boards

Journal of Clinical Microbiology, 1/1996 – 12/2004; 1/2006 – Present

Clinical and Vaccine Immunology, 1/2005 – 7/2012

 

Recent Publications

Qureshi, AA, Guan, XQ, Reis, JC, Papasian, CJ, Jabre, S, Morrison, DC, Qureshi, N. 2012. Inhibition of nitric oxide and inflammatory cytokines in LPS-stimulated murine macrophages by resveratrol, a potent proteasome inhibitor. Lipids in Health and Disease. 11:76

Fu, M., Miao, R., Huang, S., Zhou, Z., Quinn, T., Van Treek, B., Nayyar, T., Dim, D., Jiang, Z., Papasian, C., Y Chen, Y., and Liu, G. 2013. Targeted Disruption of MCPIP1/Zc3h12a Results in Fatal Inflammatory Disease. Immunol. Cell Biol. doi:10.1038/icb.2013.11

Qureshi, A.A., Khan, D.A., Mahjabeen, W., Papasian, C.J. and Qureshi, N. 2013. Nutritional Supplement-5 with a Combination of Proteasome Inhibitors (Resveratrol, Quercetin, δ-Tocotrienol) Modulate Age-Associated Biomarkers and Cardiovascular Lipid Parameters in Human Subjects. J. Clin. Experimental Cardiology. 4:238.

Zhou Z, Miao R, Huang S, Elder B, Quinn T, Papasian CJ, Zhang J, Fan D, Chen YE, Fu M. 2013. MCPIP1 Deficiency in Mice Results in Severe Anemia Related to Autoimmune Mechanisms. PLoS One. 2013 Dec 6;8(12):e82542. doi: 10.1371/journal.pone.0082542

Pei YF, Zhang L, Liu Y, Li J, Shen H, Liu YZ, Tian Q, He H, Wu S, Ran S, Han Y, Hai R, Lin Y, Zhu J, Zhu XZ, Papasian CJ, Deng HW. 2014. Meta-analysis of genome-wide association data identifies novel susceptibility loci for obesity. Hum Mol Genet. 23(3):820-30. doi: 10.1093/hmg/ddt464

Huang HL, Lv C, Zhao YC, Li W, He XM, Li P, Sha, AG, Xiao Tian X, Papasian CJ, Deng HW, Lu GX, Xiao HM. 2014. Mutant ZP1 in Familial Infertility. NEJM In Press

Photo of Nilofer Qureshi, Ph.D.
Nilofer Qureshi, Ph.D.
Director – Molecular & Cellular Immunology, Professor Immunology Work MG-CO5E Home Phone: (816) 235-1965
  • Ph. D. in Physiological Chemistry, Medical School, University of Wisconsin, Madison, WI
More info

Research Interests:

To develop novel therapeutic approaches to treat septic shock and inflammation.

We were the first to establish the complete structure of the lipid A moiety of the enterobacterial lipopolysaccharide (LPS), developed monophosphoryl lipid A as an effective adjuvant and Rhodobacter sphaeroides diphosphoryl lipid A as a powerful LPS antagonist in both in vitro and in vivo systems. Our recent research centers on the biology of LPS, especially, with regards to its effect on the ubiquitin-proteasome pathway (UPP) in macrophages and septic shock. We initially demonstrated that the LPS-induced cytokines are dependent on the composition of proteasome’s subunits present in the macrophages. We are working on a novel therapeutic approach for septic shock based upon proteasome inhibitors and antibiotics. We are also establishing the identity of ubiquitinated proteins in the LPS-induced signal transduction that are degraded by the proteasome in murine macrophages and human cells. Our conclusion from these studies is that the proteasome is a central regulator of macrophage function and inflammation and is involved in several diseases such as septic shock, cardiovascular problems, cancer and asthma.

 

Selected Publications : out of a total of over 130

Qureshi N, Perera P-Y, Shen J, Zhang G, Lenschat A, Spptter G, Morrison DC, Vogel SN. The proteasome as a LPS-binding protein in macrophages: Differential effects of proteasome inhibition on LPS-induced events. J Immunol. 2003, 171:1515-1525.

Qureshi N, Vogel SN, Van Way III, Papasian C, Qureshi AA, Morrison DC. The proteasome, a central regulator of Inflammation and macrophage function. Immunologic Research 2005, 31/3:243-260.

Shen J, Reis J, Morrison DC, Papasian C, Sreekumar R, Kolbert C, Qureshi AA, Vogel SN and Qureshi N: Key Inflammatory signapng pathways are regulated by the proteasome. Shock 2006, 25:472-484.

Reis J, Guan X-Q, Kisselev AF, Papasian CJ, Qureshi AA, Morrison DC, Van Way C III, Vogel SN, and Qureshi N. LPS-induced formation of immunoproteasomes: TNF-α and nitric oxide production are regulated by altered composition of proteasome-active sites. Cell Biochemistry and Biophysics (in press 2010).

Reis J, Hassan F, Guan X-Q, Shen J, Monaco JJ, Papasian CJ, Qureshi AA, Van Way C III, Vogel SN, Morrison DC, and Qureshi N. LMP Subunits of the proteasomes regulate the TRIF/TRAM pathway. Cell Biochemistry and Biophysics (in press 2010).

Photo of Gary Salzman, M.D.
Gary Salzman, M.D.
Professor of Medicine
  • Specialty: Pulmonary
  • Bachelor of Arts: University of Missouri-Kansas City
  • Medical School: University of Missouri-Kansas City
  • Internal Medicine Residency: Wake Forest University
  • Pulmonary Fellowship: University of Missouri-Kansas City
More info
Research Interests

In 1999 UMKC School of Medicine led by Gary A. Salzman MD, FCCP in partnership with Truman Medical Center and Children’s Mercy Hospital established the UMKC Asthma Clinical Research Center (ACRC) funded by a $500,000 grant over five years from the American Lung Association (ALA). In 2004 UMKC was awarded increased funding from the American Lung Association of $750,000 over 5 years.  Recently funding was extended for another 3 years until 2012.  The American Lung Association- Asthma Clinical Research Centers (ALA-ACRC) has successfully completed five clinical trials with several additional trials under way or in preparation. Currently there are 17 clinical centers and a data coordinating center at Johns Hopkins University.

Why did the ALA fund this large network? Health care providers caring for patients with asthma need answers quickly to provide the best care for their patients. Clinical studies performed at one center or even three or four centers may take up to five years to enroll enough subjects to answer such important questions.

The ALA recognized that 17 clinical centers will be able to enroll a large number of subjects in a relatively short period of time so the studies’ results can be published and health care providers can have the answers they need to provide the best evidence-based care to their patients with asthma.

Another advantage of a large network of clinical centers is the ability to enroll subjects from diverse populations. The populations represented in the ALA-ACRC studies include the same type of patients encountered by health care providers across the country.
Five practical and clinically important questions addressed by the ALA-ACRC are summarized below.

Vaccine safety

Is the influenza vaccine safe for patients with asthma?
The ALA-ACRC Network’s first endeavor was the Study of Inactivated Influenza Vaccine in Asthmatics (SIIVA). Influenza causes substantial morbidity in adults and children with asthma. However, the rate of vaccination for patients with asthma has been low partly due to fears of increased exacerbations from the vaccine.

The purpose of SIIVA was to evaluate the safety of the influenza vaccine in patients with asthma. The trial enrolled 2,032 participants in a three-month period between September and November 2000. Results showed rates of asthma exacerbations between vaccine and placebo injections were equivalent in a diverse population of adults and children with asthma, including severe asthma.  The results were published in the New England Journal of Medicine.

Health care providers should encourage patients with asthma to be immunized. Not only is the vaccine safe in this population, but vaccination also reduces the morbidity and mortality associated with influenza in patients with asthma.

Add-on controller medications

Which add-on controller medications work well for patients with uncontrolled asthma?
The ALA-ACRC Network’s second clinical trial was the Effectiveness of Low Dose Theophylline as Add-On Therapy in Treatment of Asthma (LODO).  Current guidelines recommend adding a controller medication to the treatment regimen of poorly controlled patients with asthma. Theophylline, a relatively inexpensive asthma medication, and anti-leukotriene agents such as montelukast, are convenient choices because both are once-a-day medications taken by mouth.
The comparative effectiveness of these two add-on treatments for poorly controlled asthma is unknown. LODO is the first clinical trial to directly compare theophylline to both active (montelukast) and placebo control.

The study enrolled 489 adolescents and adults with poorly controlled asthma over an 11-month period between 2001 and 2002.  The primary outcome was the rate of episodes of poor asthma control (EPACs). An EPAC is a composite measure of asthma control including measures of asthma control, need for medical care, and lung function.

Results showed neither low-dose theophylline nor montelukast decreased the rate of EPACs in patients with poorly controlled asthma as compared to the placebo group.  Both treatments did, however, improve lung function as measured by spirometry.

In a sub-group of patients not taking inhaled corticosteroids (ICS), monotherapy low-dose theophylline resulted in both statistically and clinically significant improvements in asthma control and symptoms. Montelukast was less effective in patients not on an ICS. As such, low-dose theophylline may provide an effective, safe and low-cost treatment alternative for patients with poorly controlled asthma who can’t or won’t use ICS because of side effects, preference, or cost.

Step-down therapy

Which step-down therapy options work well for patients with mild asthma?

Current guidelines for the treatment of patients with mild persistent asthma are to establish control of symptoms using inhaled corticosteroids and then “step-down” therapy to the minimum needed to maintain control. Although step-down therapy has been studied in patients with moderate to severe asthma, it hasn’t been systematically evaluated in patients with mild asthma. This was the purpose of the Leukotriene Modifier or Corticosteroids or Corticosteroid-Salmeterol (LOCCS) trial.

A large number of patients with asthma have a mild form of the disease. Encouraging patient adherence to asthma treatment regimens continues to present challenges. Providing patients with convenient, efficacious alternative treatments associated with fewer side effects could enhance adherence and reduce unnecessary medication exposure.

This clinical trial compared three alternative treatments for patients whose asthma was well controlled on low-dose inhaled corticosteroids. The treatment groups were fluticasone (100 mg twice a day), fluticasone plus salmeterol (100/50 mg once daily) or montelukast (10 mg or 5 mg daily for adults and children, respectively). The study randomized 500 children and adults; participant follow-up was completed in July 2005.

Results showed patients with asthma well controlled on twice-daily inhaled fluticasone can be stepped-down to once daily fluticasone/salmeterol without increased rates of treatment failure.

Stepping-down to montelukast resulted in an increase in treatment failures and decreased asthma control. Notably, however, there were a high number of symptom-free days for patients in all treatment groups, including 79 percent of days for patients taking montelukast over a four-month follow-up period.  Hence, oral montelukast isn’t as effective as either low-dose ICS (twice a day) or a low-dose ICS with salmeterol (once daily), but montelukast still provided good asthma control for most patients. The results were published in the New England Journal of Medicine.

Patient education

Are the effects of patient education real or not?

The Trial of Asthma Patient Education (TAPE) was designed to evaluate the effect of patient education on the treatment response to both placebo and montelukast. The National Heart Lung Blood Institute-funded trial completed enrollment in 2005, eight months ahead of schedule.

Patients randomized to montelukast or placebo was randomized again to receive either an enhanced presentation of the study treatment or a neutral presentation. The enhanced presentation was designed to increase expectancy of therapeutic benefit.

We compared effects of the enhanced presentation independently in the montelukast and placebo groups. This comparison addressed the question — does increasing expectancy improve outcomes equally in active treatment and placebo groups?

The usual care group was compared to the placebo group receiving the neutral presentation to estimate the placebo effect. Results showed the placebo and education effects were small for measures of lung function. However, there were effects on symptom indices such as Asthma Control Score.

Furthermore, “nocebo” effects were observed on side effects, such that more patients reported headache in the placebo group after receiving information about possible side effects than those on placebo who didn’t receive similar information. These results address the specific question about the best ways to evaluate new therapies for asthma and, more generally, how the use of placebo may affect the results of clinical trials.

The main results of the trial are currently being prepared for publication as well as results from several sub-studies evaluating adherence and education effects.

GERD & asthma

Can treatment with a proton pump inhibitor (PPI) of gastroesophogeal reflux disease improve asthma control?

GERD is common in patients with asthma, even in patients who have no symptoms of heartburn. It’s predicted that GERD may contribute to poor control of asthma but its unknown if empiric treatment of GERD in patients with poorly controlled asthma can improve control.

Two complementary clinical trials funded by the NHLBI in adults and children were  conducted by the ALA-ACRC. Both trials examine whether treatment with a PPI for GERD will improve asthma control in patients with poorly controlled asthma despite relatively high doses of inhaled steroids. Subjects undergo esophageal pH monitoring for the accurate diagnosis of GERD and have methacholine challenge testing to determine changes in bronchial reactivity. The adult study was completed in 2009 and demonstrated no improvement in asthma control with high dose proton pump inhibitor treatments. The results were published in the New England Journal of Medicine.  The pediatric study will be completed in 2011.

The ALA-ACRC has provided answers to important clinical questions for health care providers working in the trenches caring for asthma patients every day. Investigators on the ALA-ACRC steering committee are planning several future studies to improve the quality of life for adults and children living with asthma.  We recently have acquired funding from the NIH for two additional studies.  One study evaluates the administration of Soy supplements to uncontrolled asthmatics to determine if there is improved asthma control.  The other study evaluates the treatment of allergic rhinitis/sinusitis on asthma control.

The UMKC ACRC is one 17 centers nationwide undertaking a multi-center research approach to discovering improved methods to manage asthma with the long term goal to find a cure for asthma.  UMKC joins Johns Hopkins, Duke, Washington University in St. Louis, and many other prestigious universities in the largest industry independent research consortium to ever study asthma.

UMKC Lung Research Center

The Lung Research Center at UMKC was started by Dr. Salzman in 2005 to expand on the successes in clinical asthma research to include collaboration with UMKC basic science researchers.  Areas of planned studies include metabolic bone disease related to the use of systemic corticosteroids, discovery of novel mechanisms of disease in sarcoidosis, lung injury related to fat embolism from long bone fractures, and the genetic characteristics of asthma.

The collaboration of the clinical and basic science investigators with expertise in many aspects of lung disease will lead to significant discoveries that will be taken from bench to bedside to improve the treatment for many types of lung disease.  The addition of an endowed chair in lung research will serve as a catalyst for the expansion of research activities and funding.  Building on the strong foundation of existing funding and the talent of existing faculty the UMKC Lung Research Center will obtain international prominence in the next five years.

Peer Reviewed Publications

The American Lung Association Asthma clinical Research Centers (including GA Salzman). Clinical Trial of Low-dose Theophylline and Montelukast in Patients with Poorly Controlled Asthma. AJRCCM 2007. 175:235-242

The American Lung Association Asthma Clinical Research Centers (including GA Salzman). Randomized Comparison of Strategies for Reducing Treatment in Mild Persistent Asthma. N Eng J Med 2007; 356:2027-2039

Salzman GA. Smoking Ruins, The Prevention of Lung Disease. Missouri Medicine 2007; 104 (3): 208-209.

Khan ZU, Salzman GA. Management of Sepsis: The Surviving Sepsis Guidelines for Early Therapy. Hospital Physician 2007; 55:21-30.

The American Lung Association Asthma Clinical Research Center (including GA Salzman). Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma. N Engl J Med 2009;360:1487-99.

M Das, GA Salzman. Pulmonary Alveolar Proteinosis: An Overview for Internists and Hospital Physicians. Hospital Practice 2010;38(1):277-280.

Cox LS, Faseru B, Mayo MS, Krebill R, Snow TS, Bronars CA, Nollen NL, Choi WS, Okuyemi KS, Salzman GA, Benowitz NL, Tyndale RF, Ahluwalia JS. Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data. Trials 2011, 12:22

Jallu SS, Salzman GA. A Case-Based Approach to Noninvasive Positive Pressure Ventilation. Hospital Practice 2011; 39(3):168-175.

The American Lung Association Asthma Clinical Research Center (including GA Salzman). Lansoprazole for Children with Poorly Controlled Asthma. JAMA. 2012;307(4):373-381

Saettele TM, Mohr J. Evaluation and Management of Acute Kidney Injury in the Intensive Care Unit. Missouri Medicine 2012:109(5):379-383

Research Support

The Leukotriene Modifier Or Corticosteroids Trial (The LOCS Trial):

A Comparison of Continued Low-Dose Inhaled Corticosteroids versus Leukotriene Modifier for Asthmatic Patients Well Controlled with Low Dose Inhaled Corticosteroids, Principal investigator. Funding from GlaxoSmithKline $4,633,888 total funding over 5 years to Asthma Clinical Research Centers 2001-2006 One of 19 principal investigators.

The Trial of Asthma Patient Education, Funding from National Heart, Blood and Lung Institute $2,570,617 total funding over 4 years to Asthma Clinical Research Centers 2002-2006. One of 19 principal investigators

Study of Acid Reflux in Asthma, Funding from National Heart, Blood and Lung Institute $3,800,627 total funding over 5 years to Asthma Clinical Research Centers 2004-2009. One of 19 principal investigators

Study of Acid Reflux in Childhood Asthma, Funding from National Heart, Blood and Lung Institute $2,414,841 total funding over 5 years to Asthma Clinical Research Centers 2007-2012 One of 20 principal investigators

American Lung Association: Asthma Clinical Research Center: 2009-2012 for $300,000. Principal Investigator

Missouri Hospital Association Regional Health Partnership Grant for Asthma Education and Research Programs- $100,000; 2002-2006. Principal Investigator

Blue Cross and Blue Shield of Kansas City: $49,875. Developing a culturally tailored smoking cessation program for heavily addicted Chronic Obstructive Pulmonary Disease (COPD) patients; Principal Investigator 2007-2009

American Lung Association Asthma Clinical Research Centers (ACRC)
The Study of Soy Isoflavones in Asthma (SOYA) National Heart, Blood and Lung Institute: R01 HL0088367-01A2- total funding $1.5 million- one of 18 ACRC multi-center co-investigators 2010-2013

American Lung Association Asthma Clinical Research Centers (ACRC) Study of Asthma and Nasal Steroids (STAN) National Heart, Blood and Lung Institute: U01 HL00895101-01A2- total funding $2.1
One of 18 ACRC multi-center co-investigators 2010-2013

Geldmacher Pulmonary Fibrosis Research Center 2012-2017 $400,000 Principal Investigator

Kim Smolderen, Ph.D.
Assistant Professor — Implementation Science Department of Biomedical & Health Informatics
  • 2012, Post-Doctoral Fellowship in Outcomes Research PRT: American Heart Association, St. Luke’s Mid-America Heart Institute
  • 2009, PhD in Medical Psychology, Tilburg University, Tilburg Netherlands
  • Research Interests: Identification of subpopulations at-risk of suboptimal health status and clinical outcomes in cardiac populations, with focus on patients with peripheral arterial disease (PAD).
Photo of Mark Steele, M.D.
Mark Steele, M.D.
Professor – UMKC Truman Medical CentersDepartment of Emergency Medicine
  • Dept Position:  Chief Medical Officer
  • Undergraduate School:  University of Missouri-Kansas City
  • Medical School:  University of Missouri-Kansas City
  • EM Residency:  Truman Medical Center/University of Missouri-Kansas City
  • ABEM Diplomate:  1984/1994/2004
More info

Biography

Dr. Steele attended the University of Missouri-Kansas City (UMKC) School of Medicine’s combined 6-year medical program receiving his BA/MD degrees in 1980.  Dr. Steele has served on the faculty in the Department of Emergency Medicine at the UMKC School of Medicine/Truman Medical Center since his graduation from residency in 1983. He was named Vice Chairman for the Department of Emergency Medicine in 1987, Program Director in 1990, and in 1997 he was selected as Chairman, Department of Emergency Medicine. In 2000, he was selected to be the first Chief Medical Officer for Truman Medical Center and became Associate Dean for Truman Medical Center Program at the UMKC School of Medicine and was promoted to full professor at the UMKC School of Medicine.  Dr. Steele is also board certified in Emergency Medicine.Academically, Dr. Steele has over 60 publications. His interests have been in the areas of infectious disease, wound care, circadian rhythms and shift work, and emergency medicine practice and work force issues.In 2002, Dr. Steele was named as one of Ingram’s Top Doctors of Kansas City. Other honors and awards include becoming a Fellow of the American College of Emergency Physicians in 1988, receiving the UMKC Alumni Achievement Award in 1990, induction as a faculty member into Alpha Omega Alpha society at the UMKC School of Medicine in 1992, receiving the UMKC Excellence in Medical Education Award in 1992 and in 2000, being the recipient of the UMKC School of Medicine E. Grey Dimond Take Wing Award.Dr. Steele’s professional memberships include the Society for Academic Emergency Medicine (SAEM), American College of Emergency Physicians (ACEP), American Academy of Emergency Medicine (AAEM), Missouri State Medical Association (MSMA), and the American Medical Association (AMA).  Dr. Steele serves as secretary-treasurer and a member of the Board of Directors, for the American Board of Emergency Medicine (ABEM), as well as chair of the Test Administration Committee, chief examiner for the oral examination, and as an item writer.

Research Interests

Dr. Steele’s research interests are in the areas of infectious disease, wound care, circadian rhythms, shift work, emergency medicine practice and workforce issues. He has published works in these areas and has presented nationally as well.

Dr. Steele currently serves as a site investigator for the EMERGEncy ID NET. The EMERGEncy ID NET is an interdisciplinary, multicenter, emergency department-based network for research on emerging infectious diseases. It was established in cooperation with the National Center for Infectious Diseases, as part of the CDC’s strategy to expand and complement existing disease detection and control activities. The network is based at 11 university-affiliated, urban hospital emergency departments with more than 900,000 combined annual patient visits.  It also was developed to be a mechanism for rapidly responding to new infectious diseases or epidemics

Current research

Strategies using Off Patient Antibiotics for Methicillin Ressistant S. aureus (“STOP MRSA”) – a multi-center, phase III, randomized, double-blind clinical trial. Mark T. Steele, M.D., Principle site investigator.

Ultrasound FIRST (STOP MRSA sub-study). Mark T. Steele, M.D., Principle site investigator.
Prevalence and risk factors for community-associated Clostridium difficile-associated disease among patients in the emergency department, Mark T. Steele, M.D., Principle site-investigator.

Bacteriology of Acute Cuteaneous Cellulitis without Drainage using Conventional Culture and Molecular Identification of Skin Biopsy Specimens. Mark T. Steele, M.D., Principle site investigator.

Utilization of emergency departments for possible exposures to biological weapons. Mark T. Steele, M.D., Principle site investigator.

Prevalence and risk factors for community-associated methicillin resistant staphylococcus aureus skin and soft tissue infections, Mark T. Steele, M.D., Principle site-investigator.

Grant Support

Strategies using Off Patient Antibiotics for Methicillin Ressistant S. aureus (“STOP MRSA”) – a multi-center, phase III, randomized, double-blind clinical trial. National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID) / Division of Microbiology and Infectious Diseases (DMID). $1,363,370 funded 2007-2011. Principle site investigator.

Continuation of an “Emergency Department Emerging Infections Sentinel Network” Center for Disease Control and Prevention and the Olive View – UCLA Medical Center. $9,000 funded 2010/2011. Principal site investigator.

Selected Publications

Moran GJ, Barrett TW, Mower WR, Krishnadasan A, Abrahamian F, Ong S, Nakase JY, Pinner RW, Kuehnert MJ, Jarvis WR, Talan DA for the EMERGEncy ID NET Study Group (Mark T. Steele, M.D., site investigator). Decision Instrument for the Isolation of Pneumonia Patients with Suspected Pulmonary Tuberculosis Admitted through U.S. Emergency Departments.  Ann Emerg Med 2009:53(5):625-632.

Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ for the EMERGEncy ID NET Study Group (Mark T. Steele, M.D., site investigator). Prevalence and risk factor analysis of trimethoprim/sulfamethoxazole and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 2008. 47(9):1150-8.

Moran GJ, Barrett TW, Mower WR, Krishnadasan A, Abrahamian F, Ong S, Nakase JY, Pinner RW, Kuehnert MJ, Jarvis WR, Talan DA for the EMERGEncy ID NET Study Group (Mark T. Steele, M.D., site investigator). Decision Instrument for the Isolation of Pneumonia Patients with Suspected Pulmonary Tuberculosis Admitted through U.S. Emergency Departments.  Ann Emerg Med 2008 (epublished).

Ong S, Nakasae J, Moran GJ, Karras DJ, Kuehnert MJ, Talan DA, for the EMERGEncy ID Net Study Group (Mark T. Steele, M.D., site investigator) Antibiotic Use for Emergency Department Patients with Upper Respiratory Infections: Prescribing Practices, Patient Expectations, and Patient Satisfaction. Ann of Em Med 2007:50:213-220.

Steele MT, Ma OJ, Nakase J, Moran GJ, Mower, WR, Ong S, Krishnadasan A, for the EMERGEncy ID Net Study Group. Epidemiology of Animal Exposures Presenting to Emergency Departments. Acad Em Med 2007;14:398-403.

Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA, the EMERGEncy ID Net Study Group (Mark T. Steele, M.D., site investigator) Methicillin-Resistant S. aureus Infections among Patients in the Emergency Department. N Engl J Med 2006;355:666-674.

Gonzales R, Camargo CA, MacKenzie T, Kersey AS, Maselli J, Levin SK, McCulloch CE, Metlay JP, and the IMPAACT Trial Investigators (Mark T. Steele, M.D., site investigator). Antibiotic Treatment of Acute Respiratory Infections in Acute Care Settings. Acad Em Med 2006;13(3):288-294.

Talan D, Abrahamian F, Moran GH, Mower WR, Alagappan K, Tiffany BR, Pollack CV, Steele MT, Dunbar LM, Bajani MD, Weyant RS, and Ostroff SM. Tetanus immunity and physician compliance with Tetanus prophylaxis practices among emergency department patients presenting with wounds. Ann Emerg Med 2004;43(3):305-314.

Karras DJ, Ong S, Moran GH, Nakase J, Kuehnert MJ, Jarvix WR, Talan DA for the EMERGEncy ID Net Study Group (Mark T. Steele, M.D., site investigator). Antibiotic use for emergency department patients with acute diarrhea: Prescribing practices, patient expectations, and patient satisfaction. Ann Emerg Med 2003;42(6):835-842.

Kwon N, Raven MC, Chiang WK, Moran GJ, Jui J, Carter RA, Goldfrank L, and the EMERGEncy ID Net Study Group (Mark T. Steele, M.D., site investigator). Emergency Physicians’ Perspectives on Smallpox Vaccination. Acad Emerg Med 2003;10:599-605.

EMERGEncy ID Net Study Group (Mark T. Steele, M.D., site investigator). Bacteriologic Analysis of Infected Human Bites. JAMA 2002 (submitted).

Mower WR, Biros MH, Talan DA, Moran GJ, Ong S, for the EMERGEncy ID Net Study Group (Mark T. Steele, M.D., site investigator). Selective Tomographic Imaging of Patients with New-onset Seizure Disorders. Acad Emerg Med 2002;9:43-47.

Ong S, Moran GJ, Talan DA, Mower WR, Tsang VCW, Pinner RW and the EMERGEncy ID Net Study Group (Mark T. Steele, M.D., site investigator). Neurocysticercusis in Radiographically Imaged Seizure Patients in U.S. Emergency Departments. Emerging Infectious Diseases 2002;8:608-613.

Talan DA, Moran GJ, Newdow M, Ong S, Mower WR, Nakase SY, Pinner, RW, Slytsker L, EMERGEncy ID Net Study Group (Mark T. Steele, M.D., site investigator). Etiology of Bloody Diarrhea among Patients Presenting to United States Emergency Departments; Prevalence of Escherichiacoli 0157: H7 and other Enteropathogens. Clin Infect Dis 2001;32:573-580.

Moran GJ, Talan DA, Mower W, Newdow M, Ong S, Nakase JY, Pinner RW, Childs JE for the EMERGEncy ID Net Study Group (Mark T. Steele, M.D., site investigator). Appropriateness of Emergency Department Rabies Post-Exposure Prophylaxis for Animal Exposures. JAMA 2000; 284(8):1001-1007.

Steele MT, Ma OJ, Watson WA. Emergency Medicine Residents’ Shift Work Tolerance and Preference. Acad Emerg Med 2000;V 7, No 6.

Steele MT, Watson WA, Ma OJ. Percentages of emergency medicine residency graduates who get their first choice of job did not change between 1995 and 1997. Am J of Emer Med 2000;V 18:No 2, pp 152-155.

Steele MT, Ma OJ, Watson WA, et al. The occupational risk of motor vehicle collisions and near crashes for emergency medicine residents after night shifts. Acad Emerg Med 1999;Vol 6:pp 1050-1053.

Steele MT. Arboviral infections of the central nervous system – United States 1996-1997. (Update on Emergency Infections: News from the Centers for Disease Control and Prevention). Ann Emerg Med 1999;33:365-367.

Talan DA, Moran GJ, Mower WR, Newdow M, Ong S, Slutsker L, Jarvis WR, Conn LA, Pinner RW, The EMERGEncy ID NET Study Group (Mark T. Steele, M.D., site investigator): EMERGEncy ID Net: An Emergency Department-Based Emerging Infections Sentinel Network. Ann Emerg Med 1998;32:703-711.

Photo of John A. Spertus, M.D., M.P.H.
John A. Spertus, M.D., M.P.H.
Professor & Daniel J. Lauer / Missouri Endowed Chair Metabolic & Vascular Disease ResearchDepartment of Biomedical & Health Informatics
  • 1993 -University of Washington
  • Research Interests: Methods for assessing patients’ health outcomes, measuring healthcare quality, and the use of information technology to guide medical decision-making based on risk-prediction models so that treatment can be safer, more cost-effective, evidence-based and patient-centered.
Photo of Gary Sutkin, M.D., M.B.A.
Gary Sutkin, M.D., M.B.A.
Professor and Program Director Associate Dean of Women’s HealthVictor and Caroline Schutte Chair in Women’s Health

Professor, Department of Biomedical and Health Informatics (Tenure) and Obstetrics and Gynecology

  • M.D. Degree: Northwestern University
  • M.B.A. Degree: J.L. Kellogg Graduate School of Management
  • Residency: Magee Womens Hospital, Pittsburgh, PA
  • Fellowship: Magee Womens Hospital, Pittsburgh, PA
  • Certification: American Board of Obstetricians and Gynecologists, Subspecialty Female Pelvic Medicine and Reconstructive Surgery
Show Bio

Biography

Gary Sutkin is the Associate Dean and Victor and Caroline Schutte Chair in Women’s Health. He is a Professor with tenure in the Department of Obstetrics and Gynecology and the Department of Biomedical and Health Informatics.

Dr. Sutkin comes to the University of Missouri Kansas City from the University of Pittsburgh. There he was in the Academy of Master Educators and directed the Obstetrics and Gynecology core clerkship. His research centered on surgical education and the prevention of postoperative urinary tract infections. He was a co-investigator in the NIH Pelvic Floor Disease Network. He contributed to the establishment of the Nazarbayev School of Medicine in Astana Kazakhstan.

Dr. Sutkin’s research interests center on surgical safety and error prevention. He is interested in how communication between attending and resident surgeons impact patient outcome. He collaborates with a cognitive psychologist and members of the Department of Civil and Mechanical Engineering.

He is a practicing Urogynecologist and specializes in women with pelvic floor prolapse. He provides both reconstructive pelvic surgery and non-surgical treatments for women with pelvic organ prolapse, urinary incontinence, and other pelvic floor disorders.

Dr. Sutkin was born in San Antonio and grew up in Richardson, Texas. He attended Northwestern University’s Honors Program in Medical Education, worked at the federal Reserve bank in Chicago, and attained his BS, MD, and MBA degrees at Northwestern. He is an avid Northwestern fan.

Awards
  • Association of Professors of Gynecology and Obstetrics Teaching Award – 2002
  • Association of Professors of Gynecology and Obstetrics/Solvay Scholar – 2002-2003
  • Alpha Omega Alpha Society – 2003
  • Texas Tech University Health Sciences Center Dean’s Clinical Science Teaching Award – 2006
  • Council on Resident Education in Obstetrics and Gynecology Teaching Award – 2011
  • Residency Program Top 10% Golden Apple Teaching Award – 2011
  • Appointment to University of Pittsburgh School of Medicine Academy of Master Educators – 2012
  • Finalist, Patil Teaching Innovation Award – 2015
Research Interests
  • Surgical error prevention and communication
  • Intraoperative teaching
  • Midurethral sling surgery
  • Postoperative Urinary tract infections
Selected Publications
  1. Paradis E, Sutkin G. Beyond a Good Story: From Hawthorne Effect to Reactivity in Health Professions Education Research. Medical Education. 2016 Publication pending.
  2. Markland AD, Jelovsek E, Whitehead WE, Andy UU, Newman DK, Dyer K, Harm-Ernandes I, Cichowski S, McCormick J, Rardin C, Sutkin G, Shaffer A, Meikle S. Implementation of a Multi-site Manometric Biofeedback Intervention with Anorectal Manometry for the Treatment of Fecal Incontinence in Women. Neurogastroenterology and Motility. 2016 Publication pending.
  3. Lowder J, Oliphant S, Shepherd J, Ghetti C, Sutkin G. Genital Hiatus Size is Associated with and Predictive of Apical Vaginal Support Loss. Am J Obstetrics Gynecology. 2015; PMID: 26719211
  4. J. Eric Jelovsek, Alayne D. Markland , William E. Whitehead, Matthew D. Barbe, Diane K. Newman, Rebecca G. Rogers, Keisha Dyer, Anthony Visco, Vivian W. Sung MD, Gary Sutkin, Susan F. Meikle Marie G. Gantz. Controlling anal incontinence by performing anal exercises with biofeedback or loperamide (CAPABLe) trial: Design and methods. Contemp Clin Trials. 2015;44, 164-74. PMID: 26291917
  5. Sutkin G, Littleton EB, Kanter SL. How surgical mentors teach: A classification of in vivo teaching behaviors part 2: Physical teaching guidance. Journal of Surgical Education. 2015; 72(2), 251-7. PMID: 25468768
  6. Sutkin G, Littleton EB, Kanter SL. How surgical mentors teach: A classification of in vivo teaching behaviors part 1: Verbal teaching guidance. Journal of Surgical Education. 2015;72(2), 243-50. PMID: 25456208
  7. Zimmern P, Litman HJ, Nager CW, Lemack GE, Richter HE, Sirls L, Kraus SR, Sutkin G, Mueller ER. Effect of aging on storage and voiding function in women with stress-predominant urinary incontinence. J Urol. 2014 Feb 8. pii: S0022-5347(14)00131-1. doi: 10.1016/j.juro.2014.01.092. PMID: 24518790.
  8. Frankman EA, Alperin M, Sutkin G, Meyn L, Zyczynski HM. Mesh exposure and associated risk factors in women undergoing transvaginal prolapse repair with mesh. Obstet Gynecol Int. 2013;2013:926313.  doi: 10.1155/2013/926313. Epub 2013 Sep 8. PMID: 24194763; PMCID: PMC3782123.
  9. Sutkin G, Dzialowski K. A gynaecologic clinic dedicated to student teaching. Clin Teach. 2013 Jun;10(3):181-5. doi: 10.1111/j.1743-498X.2012.00633.x. PMID: 23656681
  10. Nager CW, Brubaker L, Litman HJ, Zyczynski HM, Varner RE, Amundsen C, Sirls LT, Norton PA, Arisco AM, Chai TC, Zimmern P, Barber MD, Dandreo KJ, Menefee SA, Kenton K, Lowder J, Richter HE, Khandwala S, Nygaard I, Kraus SR, Johnson HW, Lemack GE, Mihova M, Albo ME, Mueller E, Sutkin G, Wilson TS, Hsu Y, Rozanski TA, Rickey LM, Rahn D, Tennstedt S, Kusek JW, Gormley EA; Urinary Incontinence Treatment Network. A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med. 2012 May 24;366(21):1987-97. doi: 10.1056/NEJMoa1113595. Epub 2012 May 2. PMID: 22551104; PMCID: PMC3386296
  11. Skoczylas LC, Littleton EB, Kanter SL, Sutkin G. Teaching techniques in the operating room: the importance of perceptual motor teaching. Acad Med. 2012 Mar;87(3):364-71. doi: 10.1097/ACM.0b013e31824484a0. PMID: 22373633.
  12. Nygaard I, Brubaker L, Chai TC, Markland AD, Menefee SA, Sirls L, Sutkin G, Zimmern P, Arisco A, Huang L, Tennstedt S, Stoddard A. Risk factors for urinary tract infection following incontinence surgery. Int Urogynecol J. 2011 Oct;22(10):1255-65. doi: 10.1007/s00192-011-1429-9. Epub 2011 May 11.  PMID: 21560012.
  13. Martirosian Smith TE, Trowbridge ER, Pastore LM, Smith SC, Brennan MC, Dooley Y, Matthews CK, Ozel B, Sutkin G, Hullfish KL. Multicenter Urogynecology Study on Education: Medical Student Educational Experiences and Knowledge Outcomes During the OBGYN Clerkship. Female Pelvic Med Reconstr Surg. 2011 Mar;17(2):100-104. PMID: 22453697.
  14. Sutkin G, Daucher J, Zyczynski H. Prolapse in the Older Woman. European Urologic Review. 2010;5:64-8.
  15. Park AJ, Barber MD, Bent AE, Dooley YT, Dancz C, Sutkin G, Jelovsek JE. Assessment of intraoperative judgment during gynecologic surgery using the Script Concordance Test. Am J Obstet Gynecol. 2010 Sep;203(3):240.e1-6. doi: 10.1016/j.ajog.2010.04.010. Epub 2010 May 21. PMID: 20494330.
  16. Nager CW, Kraus SR, Kenton K, Sirls L, Chai TC, Wai C, Sutkin G, Leng W, Litman H, Huang L, Tennstedt S, Richter HE; Urinary Incontinence Treatment Network. Urodynamics, the supine empty bladder stress test, and incontinence severity. Neurourol Urodyn. 2010 Sep;29(7):1306-11. doi: 10.1002/nau.20836. PMID: 20127832.
  17. Sutkin G, Alperin M, Meyn L, Wiesenfeld HC, Ellison R, Zyczynski HM. Symptomatic urinary tract infections after surgery for prolapse and/or incontinence. Int Urogynecol J. 2010 Aug;21(8):955-61. doi: 10.1007/s00192-010-1137-x. Epub 2010 Mar 31. PMID: 20354678.
  18. Sutkin G, Littlefield JH, Laube DW. Nursing staff assessment of residents’ professionalism and communication skills. Med Educ. 2009 Nov;43(11):1104. doi: 10.1111/j.1365-2923.2009.03461.x. Epub 2009 Oct 2. PMID: 19799729.
  19. Sutkin G, Lowder JL, Smith KJ. Prophylactic antibiotics to prevent urinary tract infection during clean intermittent self-catheterization (CISC) for management of voiding dysfunction after prolapse and incontinence surgery: a decision analysis. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Aug;20(8):933-8. doi: 10.1007/s00192-009-0885-y. Epub 2009 Apr 10. PMID: 19582384.
  20. Sutkin G, Aronoff CK. Resident front office experience: a systems-based practice activity. Med Educ Online. 2008 May 28;13:6. doi: 10.3885/meo.2008.T0000120. PMID: 20165536; PMCID: PMC2779599.
  21. Sutkin G, Wagner E, Harris I, Schiffer R. What makes a good clinical teacher in medicine? A review of the literature. Acad Med. 2008 May;83(5):452-66. doi: 10.1097/ACM.0b013e31816bee61. Review. PMID: 18448899.
  22. Sutkin G, Burley H, Zhang K, Arora N. Characteristics of good clinical educators from medical students perspectives: A Qualitative inquiry using a web-based survey system. International Journal of Healthcare Information Systems and Informatics. 2008;3(2):69-86.
  23. Sutkin G, Krohn MA, Heine RP, Sweet RL. Antibiotic prophylaxis and non-group B streptococcal neonatal sepsis. Obstet Gynecol. 2005 Mar;105(3):581-6. PMID: 15738028.
  24. Sutkin G, Mamlok V. Images in clinical medicine. Fetus papyraceus. N Engl J Med. 2004 Apr 15;350(16):1665. PMID: 15084699.

Complete list of publications

Photo of Charles W. Van Way, III, M.D.
Charles W. Van Way, III, M.D.
Professor Director UMKC Shock Trauma Research Center
  • Medical School: The Johns Hopkins University (1964)
  • Residency: General Surgery, Vanderbilt University (1971)
  • Residency: Thoracic Surgery, Vanderbilt University (1972)
  • Board Certification: General Surgery, Surgical Critical Care, Thoracic Surgery
  • Hospital Affiliations: Truman Medical Centers
More info

The UMKC Shock Trauma Research Center is engaged in research to develop new treatment strategies to reduce the amount of cell death that occurs following shock.  Besides studies in shock, the research programs of the Center include basic studies to understand the molecular events that allow cells of the immune system to “recognize” the presence of microbes and microbial products, and to communicate that information to white blood cells

Dr. Van Way’s activities have centered around hemorrhagic shock, and to exploring the basic mechanisms of cell injury during hemorrhagic shock and resuscitation, and to identify changes which produce long-term damage.   In the past several years, his research team has carried out basic and clinical studies of the genomic response to shock and injury, and has developed several potential therapeutic agents for the treatment of hemorrhagic shock.  Currently, his team is exploring the mechanisms by which cells adjust to the low-oxygen environments which characterize low perfusion states such as septic and hemorrhagic shock.

Photo of Lakshmi Venkitachalam, Ph.D.
Lakshmi Venkitachalam, Ph.D.
Assistant Professor Epidemiology & Outcomes ResearchDepartment of Biomedical & Health Informatics
  • Ph.D. — Epidemilogy, 2007 – University of Pittsburgh
  • 2011, Post-Doctoral Fellowship in Outcomes Research PRT: American Heart Association, St. Luke’s Mid-America
  • Research Interests: Use of alternative care models such as the patient-centered medical home, the chronic care model etc. to enhance translation of evidence-based best practices and meet the health and wellness needs of underserved and vulnerable populations globally. I also have a strong interest in examining cross-country variations in the use of healthcare technology and the related impact on clinical, patient-centered and economic outcomes, with a view to informing clinical practice and health policy guidelines.
Photo of Michael Wacker, Ph.D.
Michael Wacker, Ph.D.
Assistant Dean of Medical Student Research Associate Teaching ProfessorPhysiology, Basic Medical Science Work Phone: (816) 235-6069
  • University of Kansas – Ph.D. (2003)
  • Texas Christian University – B.S. (1997)
More info

Biography

Dr. Wacker joined the Department of Basic Medical Science in the School of Medicine in 2007. He currently teaches physiology in the Human Structure Function series taught to the medical school students, as well as physiology courses in the Anesthesiologist Assistant program and the Physician Assistant program. Dr. Wacker is a member of the Muscle Biology Group at UMKC with expertise in cardiac muscle physiology. The interests in his laboratory focus on agents that alter cardiac muscle function and calcium homeostasis in cardiac myocytes. Acutely, changes in calcium homeostasis can lead to arrhythmias and alteration of cardiac muscle contractility. More chronic alterations in calcium, however, can lead to remodeling of the heart as observed in cardiac hypertrophy and heart failure. Specifically, Dr. Wacker is interested in endocrine/paracrine agents which may directly alter calcium changes in cardiac myocytes via signaling mediated by membrane receptors. Recently, Dr. Wacker and the Muscle Biology Group have worked in collaboration with the UMKC Bone Biology Group on a NIH-funded project exploring mechanisms of bone-muscle crosstalk. Dr. Wacker’s laboratory has concentrated on a hormone, FGF23, released by bone cells that may play a role in directly altering cardiac function during chronic kidney disease. Additional interests in the laboratory focus on how thromboxane A2, intracellular phosphoinositide signaling, and fibrate drugs may directly alter cardiac muscle function.

 

Recent Publications

Gallagher PM, Touchberry CD, Teson K, McCabe E, Tehel M, Wacker MJ. Effects of an acute bout of resistance exercise on fiber-type specific GLUT4 and IGF-1R expression. Applied Physiology, Nutrition, and Metabolism. 38 (5): 581-586, 2013. PMID: 23668768

Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, Carney BW, Girgis M, Vincent RJ, Wetmore LA, Dawn B, Bonewald L, Stubbs JR, Wacker MJ. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. American Journal of Physiology: Endocrinology and Metabolism. 304 (8): E863-873. 2013. PMID: 23443925

Bonewald LF, Wacker MJ. FGF23 Production by Osteocytes. Pediatric Nephrology. 28 (4): 563-568. 2013. PMID: 22983423

Silswal N, Parelkar NK, Wacker MJ, Badr M, Andresen J.   PPARa-Independent Arterial Smooth Muscle Relaxant Effects of PPARa Agonists. PPAR Research. 302495. 2012. PMID: 23008696

Wacker MJ, Tevis O, Hanke J, Howard T, Gilbert W, Orr JA. Characterization of thromboxane A2 receptor and TRPV1 mRNA in cultured sensory neurons. Neuroscience Letters. 515(1):12-7. 2012. PMID: 22425716

Silswal N, Parelkar N, Wacker MJ, Brotto M, Andresen J. Phosphatidylinositol 3,5-bisphosphate increases intracellular free calcium in arterial smooth muscle cells and elicits vasocontraction. American Journal of Physiology: Heart and Circulatory Physiology. 300 (6): H2016-26. 2011. PMID: 21421826

Touchberry CD, Elmore CJ, Nguyen TM, Andresen JJ, Zhao X, Orange M, Weisleder N, Brotto M, Claycomb WC, Wacker MJ. Store-Operated Calcium Entry is Present in HL-1 Cardiomyocytes and Contributes to Resting Calcium. Biochemical and Biophysical Research Communications. 416 (1-2): 45-50. 2011. PMID: 22079292

Touchberry CD, Bales IK, Stone JK, Rohrberg TJ, Parelkar NK, Nguyen T, Fuentes O, Liu X, Qu CK, Andresen JJ, Valdivia HH, Brotto M, Wacker MJ. Phosphatidylinositol 3,5-Bisphosphate (PI(3,5)P2) Potentiates Cardiac Contractility Via Activation of the Ryanodine Receptor. Journal of Biological Chemistry. 285 (51): 40312-21. 2010. PMID: 20947503

Photo of John Qiang Wang, M.D., Ph.D.
John Qiang Wang, M.D., Ph.D.
Acting Associate Dean for Research and Professor Departments of Anesthesiology & Basic Medical Science Work M3-225 Work Phone: (816) 235-1907
  • Westport Anesthesia / Missouri Endowed Chair for Research
  • M.D. Degree: Tongji Medical University, Wuhan, China
  • MS Degree: Tongi Medical University, Wuhan, China
  • Ph.D, Degree: Shanghai Medical University, Shanghai China
  • Fellowship: Beijing Medical University, Beijing China
  • Fellowship: Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee
More info

Biography

John Q. Wang is a Westport Anesthesia/Missouri Endowed Chair in the Department of Anesthesiology and a Professor in the Departments of Anesthesiology and Basic Medical Science at UMKC School of Medicine since 2004. He earned his medical degree in Tongji Medical University in 1982 and his Ph.D. in Shanghai Medical University in 1988. Dr. Wang’s research primarily focuses on drug abuse and addiction. He currently leads a research team supported by NIH grants to conduct animal experiments from molecule to behavior and from in vitro to in vivo. In addition, Dr. Wang is interested in elucidating molecular mechanisms for anesthesia induction.

 

Selected Publications

Mao LM, Fibuch EE and Wang JQ. (2010). Decoding BDNF-LTP coupling in cocaine addiction. Neuron. 67: 679-681.

Guo ML, Fibuch EE, Liu XY, Choe ES, Buch S, Mao LM and Wang JQ. (2010). CaMKIIα interacts with M4 muscarinic receptors to control receptor and psychomotor function. EMBO J. 29: 2070-2081.

Yao H, Yang Y, Kim KJ, Bethel-Brown C, Gong N, Funa K, Gendelman HE, Su TP, Wang JQ and Buch S. (2010). Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood. 115: 4951-4962.

Mao LM, Wang W, Chu XP, Zhang GC, Liu XY, Yang YJ, Haines M, Papasian CJ. Fibuch EE, Buch S, Chen JG, Wang JQ. (2009). Stability of surface NMDA receptors controls synaptic and behavioral adaptations to amphetamine. Nat Neurosci. 12:602-610. PMC2749993.

Liu XY, Mao LM, Zhang GC, Papasian CJ, Fibuch EE, Lan HX, Zhou HF, Xu M and Wang JQ. (2009). Activity-dependent modulation of limbic dopamine D3 receptors by CaMKII. Neuron. 61:425-438. PMC2650276.

Liu XY, Chu XP, Mao LM, Wang M, Lan HX, Li MH, Zhang GC, Parelkar NK, Fibuch EE, Haines M, Neve KA, Liu F, Xiong ZG and Wang JQ. (2006). Modulation of D2R-NR2B interactions in response to cocaine. Neuron. 52:897-909.

Yang L, Mao L, Chen H, Catavsan M, Kozinn J, Arora A, Liu X and Wang JQ. (2006). A signaling mechanism from Gαq-protein-coupled glutamate receptors to gene expression: role of the c-Jun N-terminal kinase pathway. J Neurosci. 26: 971-980.

Mao L, Yang L, Tang Q, Samdani S, Zhang G and Wang JQ. (2005). The scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons. J Neurosci. 25: 2741-2752.

Yang L, Mao L, Tang Q, Samdani S, Liu Z and Wang JQ. (2004). A novel Ca2+-independent signaling pathway to extracellular signal-regulated protein kinase by coactivation of NMDA receptors and metabotropic glutamate receptor 5 in neurons. J Neurosci. 24: 10846-10857.

Photo of Shui Qing Ye, M.D., Ph.D.
Shui Qing Ye, M.D., Ph.D.
Professor & the William R. Brown / Missouri Endowed Chair Medical Genetics & Molecular MedicineDepartment of Biomedical & Health Informatics
  • 1993, PhD, University of Chicago Pritzker School of Medicine, Chicago IL
  • 1982, Doctor of Medicine, Wuhan University School of Medicine, Wuhan China
  • Research Interests: Next generation DNA sequencing, Translational Bioinformatics and integrative strategy of animal model, biochemical, cellular, molecular and omic approaches to identify new diagnostic biomarkers and novel therapeutic targets to complex human diseases such as acute respiratory distress syndrome, coronary heart disease, chronic kidney disease and drug induced liver injury.